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Abstract	  Lipid-­‐based	  nanoparticles	  have	  attracted	  attention	  as	  promising	  pharmaceutical	  carriers.	   Reports	   of	   them	   having	   inherent	   adjuvant	   properties	   make	   them	  particularly	  interesting	  as	  vaccine	  vectors;	  however,	  the	  physicochemical	  profile	  of	  an	  ideal	  nanoparticle	  for	  mucosal	  vaccine	  delivery	  remains	  unknown.	  The	  aim	  of	   this	   thesis	   work	   is	   to	   contribute	   a	   better	   understanding	   of	   the	   connection	  between	   physicochemical	   properties	   of	   lipid	   nanoparticles	   used	   as	   vaccine	  carriers	  and	  the	  activation	  of	  the	  immune	  response	  at	  several	  different	  levels	  of	  complexity.	  As	  combined	  antigen	  and	  adjuvant,	  we	  used	  a	  novel	   fusion	  protein	  comprising	   the	   Cholera	   toxin	   A1	   subunit,	   combined	   with	   either	   the	   M2e	   or	  Ealpha	  peptide	  and	  a	  dimer	  of	  the	  D	  subunit	  of	  Staphylococcus	  aureus	  protein	  A.	  This	  fusion	  protein	  was	  coupled	  to	   liposomes	  and	  lipodisks	  with	  systematically	  varied	  poly(ethylene	  glycol)	  (PEG)	  content,	  protein	  load,	  rigidity	  and	  size/shape.	  Firstly,	  a	  detailed	  characterization	  of	  the	  biological	  response	  in	  vitro	  and	  in	  vivo,	  in	   a	   mouse	   model,	   to	   two	   types	   of	   fusion	   protein-­‐carrying	   lipid	   particles	   was	  performed.	  Compared	  with	  the	   free	   fusion	  protein,	  which	   is	   in	   itself	  already	  an	  effective	   vaccination	   compound,	   the	   result	   showed	   that	   the	   non-­‐PEGylated	  liposomes	   more	   efficiently	   induce	   both	   cell-­‐	   and	   antibody-­‐mediated	   immune	  responses	   as	  well	   as	   protection	   against	   a	   lethal	   virus	   challenge	   than	   both	   free	  fusion	   protein	   and	   the	   PEGylated	   liposomes.	   Secondly,	   an	   in	   vitro	   study	   was	  performed,	   focusing	  on	  elucidating	  the	  effect	  of	   the	  physicochemical	  properties	  of	   the	   carrier	   particle	   on	   processing,	   in	   particular	   the	   antigen	   presentation	   in	  major	   histocompatibility	   complex	   class	   II	   (MHC	   II),	   by	   dendritic	   cells.	  Out	   of	   6	  different	   formulations,	  which	  varied	  with	   respect	   to	  PEGylation,	   fusion	  protein	  load,	  membrane	  rigidity,	  size	  and	  shape	   it	  was	   found	  that	  only	   the	  DSPC-­‐based	  liposome	   formulation,	   the	   only	   liposome	   formulation	   in	   gel	   phase,	  was	   able	   to	  increase	  antigen	  presentation	  compared	  to	  free	  fusion	  protein.	  Additionally,	  this	  formulation	   lead	   to	   an	   increased	   amount	   of	   surface-­‐bound	   MHC	   II,	   indicating	  that	  the	  liposomes	  themselves	  might	  have	  an	  immunostimulatory	  effect,	  making	  them	   a	   promising	   candidate	   for	   further	   evaluation	   as	   a	   vaccine	   carrier	   with	  inherent	  adjuvant	  properties.	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“I	  checked	  it	  very	  thoroughly	  and	  that	  quite	  definitely	   is	  the	  answer.	   I	  
think	   the	   problem,	   to	   be	   quite	   honest	   with	   you,	   is	   that	   you’ve	   never	  
actually	  known	  what	  the	  question	  is.”	  
	   -­‐	  Deep	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  in	  The	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  Guide	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  the	  Galaxy	  	  by	  Douglas	  Adams	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Introduction	  Edward	   Jenner’s	   trials	   with	   conferring	   protection	   against	   smallpox	   through	  controlled	   infection	  with	   the	   relatively	   harmless	   cowpox	   virus	   in	   the	   late	   18th	  century	   is	   often	   cited	   as	   the	   birth	   of	  modern	   vaccinology.[1]	   Indeed,	   his	  work	  marked	  the	  initiation	  of	  the	  efforts	  that	  lead	  to	  eradication	  of	  smallpox	  in	  1979	  in	  what	   is	  arguably	  one	  of	   the	  biggest	  achievements	  of	  modern	  medicine.[2]	  Over	  these	   centuries,	   vaccine	   technology	  has	   developed	   from	   the	   early	   inoculations,	  where	   pus	   from	   lesions	   of	   infected	   persons	   was	   used;	   to	   safer,	   industrially	  produced	   vaccines	   containing	   inactivated	   whole	   viruses.	   Although	   such	  strategies	  have	  proven	  successful	   in	  the	  past,	   they	  have	  limitations	  that	  remain	  to	   be	   overcome	   and	   modern	   vaccination	   strategies	   aim	   at	   circumventing	  vaccination	  based	  on	  whole	  pathogens.	  This	   is	  motivated	  by	   the	   fact	   that	  using	  whole	  pathogens	  is	  not	  optimal	  from	  a	  safety	  perspective	  but	  also	  by	  the	  fact	  that	  such	   a	   strategy	   is	   not	   ideal	   for	   rapidly	  mutating	   organisms,	   such	   as	   influenza,	  since	  the	  vaccines	  need	  to	  be	  tailored	  to	  the	  specific	  strain	  causing	  the	  infection.	  As	  a	  consequence,	  vaccines	  based	  on	  whole	  pathogens	  can	  thus	  not	  be	  produced	  far	  in	  advance	  of	  the	  actual	  outbreak.	  Simultaneously,	  the	  growing	  prevalence	  of	  antibiotic	  resistance	  forces	  us	  to	  rely	  more	  and	  more	  on	  preventative	  measures,	  such	  as	  vaccines.[3]	  Additionally,	  our	  modern	  travel	  habits	  make	  us	  vulnerable	  to	   rapid	   regional	   and	   global	   spread	   of	   infectious	   diseases.[4,	   5]	   Further,	   the	  situation	   is	   worsened	   by	   traditional	   means	   of	   vaccine	   distribution,	   which	  generally	   gathers	   large	   groups	   of	   people	   in	   limited	   spaces	   to	   have	   the	   vaccine	  administered	   systemically	   by	   medically	   trained	   personnel	   through	   means	   of	  injection.	  Taken	  together,	  this	  means	  that	  the	  response	  time	  for	  an	  unanticipated	  new	  strain	  of	  a	  pathogen	  remains	  long,	  while	  other	  treatment	  options	  are	  fewer	  and	   transmission	   is	   faster	   than	   ever.	   The	   demands	   on	   the	   next	   generation	   of	  vaccines	  are	  thus	  clear:	  they	  should	  be	  universal,	  effective	  against	  all	  strains	  of	  a	  particular	  pathogen;	  administration	  should	  be	  fast	  and	  easy,	  ideally	  not	  requiring	  trained	  personnel;	  and,	  of	  course,	  they	  should	  be	  safe	  and	  effective.	  	  	  Universal	  vaccines	  can	  in	  principle	  be	  created	  by	  using	  evolutionarily	  conserved	  subcomponents	   rather	   than	   inactivated	   whole	   pathogens.[6]	   The	   composition	  and	  production	  of	  subunit	  vaccines	  are	  tightly	  controllable,	  usually	  making	  them	  safer	   with	   fewer	   manufacturing	   and	   regulatory	   concerns.	   They	   are	   however	  generally	   less	   immunogenic	   than	   formulations	   comprising	   whole	   pathogens.	  Ease	  of	  administration	  could	  be	  achieved	  by	  making	  mucosal	  vaccines,	  which	  are	  administered,	   for	   example,	   orally	   or	   intranasally.[7]	   Mucosal	   vaccines	  additionally	   have	   lower	  demands	  on	  purity	   compared	   to	   injected	   vaccines	   and	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can	  achieve	  local	  immune	  activation,	  which	  cannot	  be	  achieved	  through	  systemic	  administration.[7]	  However,	  the	  environment	  at	  the	  mucosal	  interfaces	  naturally	  contains	  a	  high	  abundance	  of	  commensal	  (“healthy”)	  bacteria	  and	  other	  potential	  triggers	   for	   the	   immune	  system,	   for	  example	  pollen	  and/or	   food	  proteins.	  As	  a	  consequence,	  the	  mucosal	  immune	  system	  is	  not	  easily	  triggered.[8]	  Thus,	  both	  current	  subunit	  and	  mucosal	  vaccine	  candidates	  often	  require	  large	  amounts	  of	  antigen	  and	  strong	  adjuvants,	   i.e.	   immunostimulatory	  agents	   that	  enhances	   the	  immune	  response,	  to	  be	  effective.	  	  	  To	   improve	   the	   performance	   of	   mucosal	   subunit	   vaccines,	   particulate	   carrier	  systems	   have	   been	   proposed	   as	   a	   promising	   strategy.	   The	   advantage	   of	   such	  systems	   is	   that	   they	   can	  protect	   antigen	   from	  premature	  degradation	  while,	   at	  the	   same	   time,	   exhibit	   immunostimulatory	   effects	   in	   their	   own	   right.[9]	   Lipid-­‐based	   delivery	   vehicles	   have	   been	   used	   with	   success	   for	   delivery	   of	   various	  drugs,	   macromolecules	   as	   well	   as	   diagnostic	   agents	   in	   the	   clinic	   and	   are	  promising	   candidates	   also	   as	   vaccine	   vectors.[10]	   Lipid-­‐based	   particles	   are	  vastly	   customizable	   when	   it	   comes	   to	   their	   composition	   and	   physicochemical	  properties,	   which	   is	   one	   of	   their	  main	   advantages.	   However,	   this	   gives	   rise	   to	  questions	  about	  how	  to	  best	  design	  vaccine	  carriers	  to	  achieve	  and	  modulate	  the	  immune	   activation	   that	   follows	   administration.	   Indeed,	   it	   yet	   remains	   to	   be	  understood,	   in	   the	   context	   of	   vaccine	   vectors,	   how	   the	   physicochemical	  properties	  of	  the	  carrier	  affects	  the	  type	  of	  uptake	  mechanism	  that	  is	  employed,	  how	   the	   uptake	   process	   progresses	   and	   how	   it	   in	   turn	   affects	   the	   antigen	  presentation	   as	   well	   as	   modulation	   of	   the	   larger	   scale	   immune	   response	   that	  follows.	  As	  a	  consequence,	  being	  able	  to	  pinpoint	  which	  properties	  are	  decisive	  for	  efficient	  uptake	  and	  presentation	  by	  dendritic	  cells	  and	  further	  development	  of	  immunity	  and	  thus	  identify	  promising	  candidates	  at	  an	  early	  stage	  might	  help	  us	  rationalize	  the	  process	  of	  designing	  vaccine	  formulations.	  	  	  	  The	   aim	   of	   this	   thesis	   work	   is	   to	   contribute	   a	   better	   understanding	   of	   the	  connection	   between	   physicochemical	   properties	   of	   lipid	   nanoparticles	   used	   as	  vaccine	  carriers	  and	  the	  activation	  of	   the	   immune	  response	  at	  several	  different	  levels	  of	  complexity.	  Firstly,	  a	  detailed	  characterization	  of	  the	  biological	  response	  
in	   vitro	   and	   in	   vivo,	   in	   a	   mouse	   model,	   to	   two	   types	   of	   antigen-­‐carrying	   lipid	  particles	  is	  described	  in	  Paper	  I.	  In	  a	  second	  step,	  we	  focused	  on	  an	  in	  vitro	  model	  to	  specifically	  quantify	  the	  antigen	  presentation	  (in	  Paper	  II),	  which	  enabled	  us	  to	   more	   rapidly	   identify	   a	   formulation	   with	   improved	   immunostimulatory	  properties.	   In	   addition,	   we	   have	   also	   started	   to	   explore	   single-­‐cell	   imaging	   to	  investigate	   the	   uptake	   process	   of	   vaccine	   nanoparticles	   by	   antigen	   presenting	  cells,	   representing	   the	   very	   first	   step	   in	   activating	   the	   immune	   response	   (in	  additional	  experimental	  data).	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The	  thesis	  has	  the	  following	  disposition:	  you	  are	  currently	  reading	  Chapter	  1	  and	  should	  already	  know	  what	   the	   thesis	  work	   is	  about.	  Chapter	  2	  provides	  a	  brief	  background	   to	   the	   immune	   system	   and	   the	   challenges	   and	   opportunities	   it	  provides	   for	   vaccination.	   Chapter	   3	   introduces	   the	   concept	   of	   lipids	   and	   lipid	  assemblies	   and	   how	   they	   can	   be	   used	   as	   carrier	   particles,	   while	   Chapter	   4	  focuses	   on	   the	   use	   of	   such	   particles	   as	   carriers	   in	   mucosal	   vaccines	   against	  infectious	  diseases.	  The	  techniques	  used	  for	  characterization	  of	  lipid	  particles	  as	  well	   as	   particle	   uptake	   and	   antigen	   presentation	   by	   cells	   are	   introduced	   in	  Chapter	  5.	  In	  Chapter	  6,	  the	  results	  of	  the	  appended	  papers	  are	  summarized	  and	  finally,	  Chapter	  7	  presents	  the	  future	  perspectives	  of	  this	  work.	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  2
Achieving	  immune	  system	  activation	  
through	  mucosal	  vaccination	  The	   immune	   system	   is	   a	   collection	   of	   mechanisms	   in	   place	   to	   recognize	   and	  defend	   the	  body	   from	  “non-­‐self”	  elements,	   enabling	  us	   to	   fend	  off	   attacks	   from	  foreign	  entities	  such	  as	  bacteria	  and	  viruses	  but	  also	  damaged	  self-­‐cells,	  such	  as	  cancer	  and	  virus-­‐infected	  cells.	  The	  immune	  system	  consists	  of	  several	  layers	  of	  defense	   that	   interact	   through	   a	   complex	   interplay	   of	   molecular	   signaling	   and	  interactions.	  	  	  	  The	   first	   line	   of	   defense	   is	   the	   innate	   immune	   system.	   It	   acts	   in	   an	   unspecific	  manner,	  meaning	   that	   it	  does	  not	  distinguish	  between	  different	  pathogens	  and	  does	   not,	   on	   its	   own,	   lead	   to	   protective	   immunity.	   The	   enzymes	   and	   acidic	  environment	   in	   the	   stomach,	   the	   complement	   system,	   natural	   killer	   (NK)	   cells	  and	  phagocytes	  (“eating	  cells”,	  for	  example	  dendritic	  cells	  and	  macrophages)	  are	  some	  of	   its	   constituents.	  Of	   particular	   relevance	   to	  mucosal	   vaccination	   is	   also	  the	  mucous	  membrane,	  which	  consists	  of	  a	  layer	  of	  connective	  tissue	  known	  as	  the	  lamina	  propria	  overlaid	  with	  tightly	  connected	  epithelial	  cells,	  which	  are	  not	  readily	   penetrable.	   On	   top	   there	   is	   a	   layer	   of	  mucus:	   a	   viscoelastic,	   negatively	  charged	   secretion	   containing,	   among	   other	   things,	   mucins	   and	   secreted	  antibodies	   (immunoglobulins)[11],	   as	   schematically	   illustrated	   in	   Figure	   1	  together	  with	   an	   overview	  of	   the	   activation	   of	   the	   adaptive	   immune	   response.	  Additionally,	   some	   of	   the	   epithelial	   cells	   are	   equipped	   with	   cilia:	   hair-­‐like	  extensions	   that	   move	   in	   a	   coordinated	   fashion.	   The	   movement	   of	   the	   cilia	  combined	   with	   the	   viscoelastic	   properties	   of	   the	   mucus	   creates	   a	   directed	  outwards	  flow	  of	  the	  mucus;	  trapping	  and	  actively	  transporting	  foreign	  matter	  in	  what	  is	  known	  as	  mucociliary	  clearance.	  	  	  The	  second	  line	  of	  defense	  is	  the	  adaptive,	  also	  known	  as	  the	  acquired,	  immune	  system;	  the	  body’s	  specific	  response	  that	  takes	  longer	  to	  be	  initiated	  but	  which,	  in	   contrast	   to	   the	   innate	   immune	   system,	   can	   discriminate	   between	   closely	  related	  pathogens.	  It	   involves	  lymphocytes:	  T	  cells	  and	  B	  cells,	  which	  recognize	  non-­‐self	   components,	  often	  referred	   to	  as	  antigens.	  The	  antigen-­‐specificity	  of	  T	  and	   B	   cells	   allows	   the	   adaptive	   immune	   system	   to	   retain	   a	   memory	   of	   past	  events,	  facilitating	  a	  faster	  and	  stronger	  defense	  upon	  subsequent	  exposures.[12]	  The	  purpose	  of	  vaccination	  is	  to	  engage	  the	  immunological	  memory	  in	  order	  to	  acquire	  protection	  without	  having	  to	  endure	  actual	  infection	  and	  the	  symptoms	  that	  entails.	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Figure	  1.	  Example	  of	  induction	  of	  the	  adaptive	  immune	  response	  through	  mucosal	  vaccination.	  	  The	  
vaccine	   needs	   to	   pass	   the	   mucosal	   barrier,	   for	   example	   by	   being	   taken	   up	   by	   an	   M	   cell,	   which	  
transports	  it	   to	  the	  other	  side	  of	  the	  mucous	  membrane.	  There,	   it	   is	  available	  for	  uptake	  by	  DCs,	  a	  
highly	  specialized	  APC,	  which	  take	  up,	  process	  and	  present	  antigen	  on	  their	  surface	  on	  MHC	  I	  and/or	  
II.	   DCs	  migrate	   to	   nearby	  mucosa-­‐associated	   lymphoid	   tissue	   where	   antigen	   presented	   on	  MHC	   I	  
activates	   naïve	   CD8+	   T	   cells,	   which	   differentiate	   into	   effector	   and	   memory	   CTLs.	   CTLs	   are	   cells	  
specialized	  in	  killing	  damaged	  cells,	  such	  as	  those	  infected	  by	  viruses	  or	  bacteria.	  Antigen	  presented	  
on	  MHC	  II	  activates	  naïve	  CD4+	  T	  cells,	  which	  differentiate	  into	  effector	  and	  memory	  Th	  cells.	  Th	  cells	  
modulate	  of	  the	  immune	  response	  through	  cytokine	  release.	  DCs	  additionally	  traffic	  antigen	  to	  the	  B	  
cell	   zone.	   Naïve	   B	   cells	   are	   activated	   by	   the	   antigen	   and	   co-­‐stimulation	   from	   Th	   cells,	   and	  
differentiate	  into	  memory	  and	  effector	  (plasma)	  cells.	  Plasma	  cells	  release	  antibodies,	  for	  example	  
sIgA,	  which	  carries	  out	  protective	  functions	  such	  as	  binding	  to	  surface	  proteins	  of	  pathogens.	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 Vaccine	  delivery	  across	  the	  mucosal	  barrier	  2.1There	  is	  a	  series	  of	  barriers	  in	  place	  that	  needs	  to	  be	  overcome	  before	  being	  able	  to	   successfully	   engage	   the	   adaptive	   immunes	   system	   to	   achieve	   protective	  immunity,	   particularly	   in	   the	   case	   of	   mucosal	   vaccines.	   The	   innate	   immune	  system	   has	   evolved	   to	   repel	   and	   degrade	   foreign	   matter	   to	   prevent	   infection.	  Accordingly,	  mucosal	  vaccines	  will,	  upon	  administration,	  immediately	  encounter	  the	  chemical	  and	  mechanical	  cleansing	  system	  that	   is	   in	  place	  at	  most	  mucosal	  surfaces.[8]	  A	  first	  hurdle	  when	  developing	  a	  vaccination	  strategy	  is	  therefore	  to	  prevent	  premature	  degradation	  of	  the	  antigen,	  which	  is	  particularly	  challenging	  in	  the	  case	  of	  oral	  immunization.[13]	  This,	  in	  turn,	  is	  the	  main	  motivation	  behind	  the	   efforts	   undertaken	   to	   improve	   the	   resistance	   of	   vaccine	   formulations	   to	  degradation	  in	  biological	   fluids,	  as	  summarized	  in	  section	  4.3.	  Once	  the	  vaccine	  has	   survived	   the	   harsh	   environment	   encountered	   at	   the	   luminal	   side	   of	   the	  mucosa,	  the	  challenge	  to	  deliver	  the	  antigen	  across	  the	  mucosa	  remains.	  In	  order	  to	   do	   this,	   the	   mucociliary	   clearance	   needs	   to	   be	   avoided	   and	   the	   mucous	  membrane	   needs	   to	   be	   traversed.[8,	   11]	   There	   are	   three	   main	   strategies	   to	  increase	   antigen	   transfer	   through	   this	   complex	   barrier.	   The	   first	   is	   to	   increase	  the	  mucopenetration	  of	   vaccine	   formulations,	   often	  by	  using	  neutrally	   charged	  and	   hydrophilic	   carrier	   particles	   in	   an	   attempt	   to	   avoid	   entrapment	   by	   the	  mucus	   (see	   section	   4.6	   for	   additional	   details).	   The	   second,	   opposite,	   strategy	  aims	   at	   increasing	   the	  mucoadhesion,	   in	   order	   to	   decrease	   the	   clearance	   rate,	  often	   by	   using	   particles	   of	   a	   positively	   charged	   and	   hydrophobic	   nature,	   as	  discussed	  in	  sections	  4.1	  and	  4.6).[14]	  The	  choice	  between	  these	  two	  strategies	  depends	   on	   the	   properties	   of	   the	   target	   mucosa.	   For	   example,	   mucoadhesive	  carrier	   particles	   can	   be	   useful	   when	   targeting	   mucosa	   with	   a	   slow	   mucus	  turnover	  rate,	  while	  mucopenetrating	  particles	  can	  be	  used	  for	  traversing	  thick	  mucus	   layers.[15]	  The	  third	  strategy	  attempts	  to	  utilize	   the	  body’s	  own	  system	  for	   transport	   across	   the	  mucosal	   barrier	   by	   targeting	  microfold	   cells	   (M	   cells)	  (see	   section	   4.7).	   M	   cells	   are	   specialized	   in	   phagocytosis	   and	   transcytosis,	   i.e.	  transport	   through	   the	   interior	   of	   the	   cell,	   of	   macromolecules,	   particles	   and	  microorganisms	  across	  the	  follicle-­‐associated	  epithelium	  (FAE)	  to	  the	  lymphoid	  tissues	   located	   in	   connection	   to	   the	   intestinal	   and	   nasal	   mucosa.[16]	   For	   this	  task,	  M	  cells	  have	  an	  intraepithelial	  pocket,	  where	  the	  antigens	  taken	  up	  from	  the	  luminal	   side	   are	   made	   available	   to	   cells	   on	   the	   other	   side	   of	   the	   mucous	  membrane.[16]	  
 Activating	  the	  adaptive	  immune	  system:	  the	  role	  of	  antigen	  presenting	  2.2
cells	  Once	  the	  vaccine	  formulation	  has	  crossed	  the	  barrier	  of	  the	  mucosa,	  it	  needs	  to	  be	  recognized	  by	  antigen	  presenting	  cells	  (APCs),	  considered	  the	  bridge	  between	  the	  innate	  and	  adaptive	  immune	  systems.	  APCs	  sample	  their	  environment	  using	  several	  different	  mechanisms	  of	  uptake,	  including	  endocytosis,	  phagocytosis	  and	  macropinocytosis.[17]	   They	   distinguish	   self	   from	   non-­‐self	   by	   recognizing	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evolutionarily	   conserved	  molecular	   structures	   exclusively	   found	   on	   pathogens	  and	  called	  pathogen-­‐associated	  molecular	  patterns	  (PAMPs).	  Examples	  of	  PAMPs	  are	   bacterial	   cell-­‐wall	   components,	   certain	   lipids,	   for	   example	   lipid	   A	   (seen	   in	  Figure	   3),	   and	   different	   forms	   of	   microbial	   nucleic	   acids.[18-­‐20]	   APCs	   use	   a	  group	   of	   receptors	   known	   as	   pattern	   recognition	   receptors	   (PRRs)	   for	   this	  discrimination	   process.	   These	   receptors	   include	   Toll-­‐like	   receptors	   (TLRs),	   C-­‐type	   lectin	   receptors	   (C-­‐LRs)	   and	   nucleotide-­‐binding	   oligomerization	   domain	  (NOD)-­‐like	  receptors.[18-­‐20]	  Ligand	  binding	  to	  PRRs	  signals	  danger	  and	  starts	  a	  signaling	   cascade	   whose	   end	   result	   is	   tuning	   of	   the	   immune	   response.	   PRR	  agonists	   are	   therefore	   often	   used	   to	   target	   vaccine	   delivery	   to	   APCs	   and	   as	  adjuvants	  to	  modulate	  the	  immune	  response	  (see	  section	  4.7).	  	  	  Once	  an	  APC	  has	  taken	  up	  antigen,	  the	  cell	  begins	  to	  mature,	  which	  leads	  to	  up-­‐regulation	  of	   the	   antigen-­‐processing	  machinery	   and	  migration	   to	   the	   lymphoid	  organs	  where	  T	  and	  B	  cells	  reside	   in	  spatially	  separate	  zones.	  After	  uptake,	   the	  antigen	  is	  processed,	  which	  involves	  the	  degradation	  of	  the	  foreign	  molecule	  into	  molecular	   fragments,	   often	   short	   peptides,	   in	   certain	   antigen-­‐processing	  compartments,	   followed	   by	   mounting	   of	   the	   peptides	   on	   Major	  Histocompatibility	  Complex	  class	  II	  (MHC	  II).	  The	  peptide-­‐MHC	  II	  complexes	  are	  then	  transported	  to	  the	  cell	  surface	  where	  they	  are	  displayed.[17]	  In	  some	  cases,	  the	  antigen	  is	  also	  presented	  on	  Major	  Histocompatibility	  Complex	  class	  I	  (MHC	  I),	  a	  process	  known	  as	  cross	  presentation,	  the	  importance	  of	  which	  is	  discussed	  further	  in	  section	  2.3.	  	  
 Inducing	  and	  tuning	  cell-­‐mediated	  immunity	  2.3One	   of	   the	  main	   functions	   of	   APCs,	   once	   they	   reach	   the	   lymphoid	   tissue,	   is	   to	  initiate	  and	   influence	   the	  nature	  of	   the	  T	   cell	   response,	  which	   is	   referred	   to	  as	  cell-­‐mediated	   immunity.	   In	   the	   context	   of	   inducing	   strong	   cell-­‐mediated	  immunity,	  a	  type	  of	  APC	  called	  dendritic	  cell	  (DC)	  is	  a	  target	  of	  choice	  for	  vaccine	  delivery	   (see	   section	   4.7).[21]	   Indeed,	   DCs	   are	   both	   exceptionally	   efficient	   at	  antigen	  uptake	  and	  processing	  and	  are	  key	  players	   in	   induction	  of	   the	  primary	  immune	  response	  (see	  Figure	  1).	  The	  presentation	  of	  antigens	  by	  DCs	  is	  required	  for	  activation	  of	  naïve	  antigen-­‐specific	  T	  cells,	  which	  can	  then	  differentiate	   into	  effector	  and	  memory	  T	  cells,	  being	  essential	  for	  long-­‐term	  immunity.	  Which	  class	  of	  MHC	  the	  antigen	  is	  presented	  on	  is	  decisive	  for	  which	  subset	  of	  T	  cells	  the	  DC	  is	  able	  to	  activate.	  	  In	   addition	   to	   association	   with	   antigen	   presented	   on	   MHC,	   T	   cells	   require	  interactions	  with	  costimulatory	  molecules,	  such	  as	  CD80	  and	  CD86,	  found	  on	  the	  surface	  of	  mature	  DCs.	  Furthermore,	  DCs	  release	  cytokines,	  which	  are	  signaling	  molecules	  that	  together	  with	  the	  costimulatory	  molecules	  act	  on	  T	  cells	  in	  order	  to	   tune	   the	   type	  of	   response	   initiated.	  More	  specifically,	   recognition	  of	  MHC	   II-­‐mounted	  antigens	  leads	  to	  the	  activation	  of	  CD4+	  T	  cells	  into	  T	  helper	  (Th)	  cells	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whose	   main	   function	   is	   to	   release	   cytokines,	   thereby	   effectively	   tuning	   the	  immune	   response	   by	   regulating	   the	   activity	   of	   other	   cells.	   Often,	   Th	   cells	   are	  divided	   into	   two	   subsets:	   those	   promoting	   cell-­‐mediated	   immunity	   (Th1)	   and	  those	  promoting	  antibody-­‐mediated,	  also	  known	  as	  humoral,	  immunity	  (Th2,	  see	  section	  2.4).	  On	  the	  other	  hand,	  cross-­‐presentation	  of	  antigens	  onto	  MHC	  I	  leads	  to	  priming	  of	  naïve	  CD8+	  T	  cells,	  generating	  cytotoxic	  T	  lymphocytes	  (CTLs)	  (see	  Figure	  1)	  that	  are	  important	  for	  the	  killing	  of,	  among	  other	  things,	  virus-­‐infected	  cells.[12]	   Particulate	   delivery	   systems	   have	   been	   shown	   to	   increase	   the	   cross-­‐presentation	   efficiency,	  making	   carrier	  particles	  particularly	   interesting	   from	  a	  vaccine	  development	  perspective.[8]	  	  
 Inducing	  humoral	  immunity	  2.4The	   other	   branch	   of	   the	   adaptive	   immune	   system,	   which	   also	   needs	   to	   be	  stimulated	  by	  vaccination,	  is	  known	  as	  humoral	  immunity.	  This	  type	  of	  immune	  response	   is	   mediated	   by	   antibodies.	   Effector	   functions	   of	   antibodies	   include	  neutralization	  of	   toxins	   and	  microbes	   through	  binding	   to	   and	  blocking	  of	   their	  surface	   proteins,	   activation	   of	   the	   complement	   system	   and	   opsonization,	   a	  process	  by	  which	  a	  pathogen	  is	  marked	  for	  destruction	  by	  phagocytes.	  	  	  Antibodies	   are	   large	   proteins	   able	   to	   bind	   to	   specific	   epitopes	   on	   antigens.	  Antibody-­‐antigen	  recognition	  is	  highly	  specific	  due	  to	  the	  fact	  that	  the	  chemical	  properties	   of	   the	   amino	   acid	   sequence	   forming	   the	   antigen-­‐binding	   site	   of	   the	  antibody	   geometrically	   and	   physicochemically	   match	   regions	   on	   the	  corresponding	   epitope	   on	   the	   antigen.	   This	   allows	   formation	   of	   a	  multitude	   of	  electrostatic	   and	   hydrophobic	   interactions	   and	   hydrogen	   bonds,	   the	   sum	   of	  which	   leads	   to	   an	   attraction.[12]	   Antibodies	   are	   classified	   into	   five	   different	  immunoglobulin	   classes	   according	   to	   their	   characteristics.	   Of	   relevance	   in	   the	  context	   of	   vaccination	   are	   IgG,	   the	   main	   serum	   antibodies,	   and	   secretory	   IgA	  which	  are	  generally	  secreted	  in	  the	  lamina	  propria	  in	  the	  mucous	  membrane	  to	  protect	   against	   infection	  at	   this	   interface.[12]	  Local	   secretion	  of	   IgA	  antibodies	  can	  only	  be	  triggered	  by	  local	  activation,	  highlighting	  the	  advantages	  of	  mucosal	  immunization	  in	  the	  context	  of	  vaccine	  development.	  	  	  Antibodies	  are	  produced	  by	  B	  cells	  (see	  Figure	  1)	  and	  exist	  in	  two	  forms:	  a	  free,	  secreted	   form	   and	   a	   cell-­‐membrane	   bound	   form	  known	   as	   the	  B	   cell	   receptor.	  The	  B	  cell	  receptor	  is	  crucial	  to	  the	  activation	  and	  differentiation	  of	  naïve	  B	  cells	  into	  memory	  B	  cells,	  which	  remain	  in	  the	  body	  to	  provide	  prolonged	  protection,	  and	  into	  plasma	  cells,	  which	  are	  the	  main	  antibody-­‐secretor	  cells.	  B	  cells	  can	  be	  stimulated	  by	  antigen	  binding	  to	  the	  B	  cell	  receptor	  alone	  and	  can,	  in	  fact,	  act	  as	  APCs.	  However,	  the	  trafficking	  of	  antigens	  by	  DCs	  to	  the	  B	  cell	  zones,	  known	  as	  follicles,	  in	  the	  lymphoid	  tissues	  greatly	  increases	  the	  likelihood	  that	  naïve	  B	  cells	  encounter	   their	   specific	   antigen.	   Additionally,	  most	   B	   cells	   require	   stimulation	  from	  activated	  Th	  cells	  to	  function	  optimally	  (see	  Figure	  1).	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 Assessing	  the	  immune	  response	  	  2.5Historically	  in	  vaccine	  development,	  a	   large	  focus	  has	  been	  placed	  on	  achieving	  antibody-­‐mediated	   immunity.[22]	   Indeed,	   antibodies	  are	   crucial	   for	  preventing	  infection	  since	  they	  can	  block	  the	  surface	  proteins	  of	  pathogens	  and	  thus	  prevent	  them	   from	   binding	   to	   and	   entering	   host	   cells.	   The	   cell	   mediated	   immunity	   is	  however	   necessary	   for	   attenuation	   and	   clearance	   of	   symptoms	   once	   infection	  has	   occurred.	   Therefore,	   a	   combination	   of	   the	   two	   is	   generally	   considered	   the	  most	  efficient	  and	  we	  thus	  aim	  to	  achieve	  engagement	  of	  both	  humoral	  and	  cell-­‐mediated	  immune	  responses	  at	  both	  a	  local	  and	  systemic	  level.[22]	  The	  intensity	  and	  quality	  of	  an	  induced	  immune	  response	  is	  typically	  assessed	  by	  measuring	  a	  set	   of	   biological	   markers.	   Different	   types	   of	   antibodies	   and	   cytokines,	   such	   as	  interleukins	   (ILs),	   are	   commonly	   quantified	   and	   indicate	   activity	   of	   certain	  branches	   of	   the	   immune	   response.	   Some	  of	   the	  more	   commonly	  used	  markers	  and	  what	  they	  indicate	  in	  the	  context	  of	  vaccine	  development	  are	  summarized	  in	  Table	  1.	  	  
Table	  1.	  Commonly	  used	  markers	  of	  immune	  activation	  following	  vaccine	  administration.	  
Marker	   Type	   of	  
molecule	  
Role	  
IgG	   Antibody	   Indicates	  activation	  of	  systemic	  humoral	  immunity.	  IgA	   Antibody	   Indicates	  activation	  of	  mucosal/local	  humoral	  immunity.	  IL-­‐4	   Cytokine	   Indicates	   Th	   cell-­‐mediated	   activation	   of	   B	   cells.	   It	   induces	   the	  differentiation	   of	   B	   cells	   into	   plasma	   cells	   and	   stimulates	  proliferation	   of	   activated	   B	   and	   T	   cells.	   IL-­‐4	   induces	  differentiation	   of	   naïve	   helper	   T	   cells	   to	   Th2	   cells,	   which	   upon	  activation	  by	   IL-­‐4	  produce	  additional	   IL-­‐4	   in	  a	  positive	   feedback	  loop.	   Additionally	   it	   up-­‐regulates	   MHC	   II	   production	   while	  decreasing	  production	  of	  Th1	  cells,	  macrophages	  and	  IFN-­‐γ. IFN-­‐γ	   Cytokine	   Indicates	  activation	  of	  APCs.	  It	  is	  produced	  predominantly	  by	  NK	  and	  natural	  killer	  T	  cells	  as	  part	  of	   the	   innate	   immune	  response,	  and	  by	  Th1	  cells	  and	  CTL	  once	  adaptive	  immunity	  develops.	  IFN-­‐γ	  is	   an	   important	  activator	  of	  macrophages	  and	   inducer	  of	  MHC	   II	  expression.	  IL-­‐2	   Cytokine	   Is	  a	  signal	  for	  differentiation	  into	  memory	  and	  effector	  T	  cells.	  IL-­‐2	  also	  has	  roles	  in	  regulation	  of	  T	  cell	  activity.	  IL-­‐17	   Cytokine	   Indicates	  activity	  of	  T	  helper	  17	   cells,	   important	   for	  maintaining	  mucosal	   barriers	   and	   clearance.	   IL-­‐17	   has	   an	   important	   role	   in	  proinflammatory	   responses	  and	   induces	   the	  production	  of	  many	  other	  cytokines.	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Lipids	  and	  lipid	  self-­‐assemblies	  Lipids	  are	  an	  important	  building	  block	  of	  many	  living	  organisms	  in	  that	  they	  are	  the	  main	  constituents	  of	  the	  cellular	  membranes.	  The	  membranes	  are	  thin,	  fluid	  films	   to	  which	   lipids	   provide	   a	   structure	   that	   allows	   for	   lateral	  movements	   of	  incorporated	   proteins	   and	   other	   biomolecules.[23]	   The	   membranes	  simultaneously	   form	   selectively	   permeable	   barriers	   that	   maintain	   appropriate	  intracellular	   concentrations	   of	   a	   vast	   number	   of	   molecules	   and	   ions,	   thus	  delineating	  organelles	  as	  well	  as	  the	  inside	  of	  a	  cell	  from	  the	  outside.[23]	  Among	  the	  variety	  of	  lipids	  found	  in	  living	  organisms,	  phospholipids	  are	  the	  ones	  most	  abundantly	   found	   in	   cell	   membranes.	   This	   type	   of	   lipids	   is	   also	   the	   main	  constituent	   of	   many	   man-­‐made	   lipid	   structures,	   including	   vaccine	   vectors.[24,	  25]	  They	  are	  made	  up	  of	  a	  hydrophobic	  tail	  consisting	  of	  two	  fatty	  acids	  linked	  by	   a	   glycerol	   backbone	   to	   a	  hydrophilic	   headgroup	  made	  up	  of	   phosphate	   and	  potentially	   another	   organic	   molecule	   (Figure	   2A).	   Based	   on	   their	   headgroup,	  naturally	   occurring	   phospholipids	   can	   be	   sorted	   into	   6	   categories:	  phosphatidylcholine	   (PC),	   phosphatidylethanolamine	   (PE),	   phosphatidylserine	  (PS),	   phosphatidylinositol	   (PI),	   phosphatidylglycerol	   (PG)	   or	   phosphatidic	   acid	  (PA).	  PS,	  PI,	  PG	  and	  PA	  are	  negatively	  charged	  while	  PC	  and	  PE	  are	  neutral	  but	  zwitterionic.	  The	  possibility	   to	   chemically	  modify	  both	   the	  head	  group	  and	   the	  tail	   region	   gives	   the	  possibility	   to	   synthesize	  phospholipids	   tailored	   to	   specific	  requirements.	   In	   this	   way,	   positively	   charged	   lipids	   have	   been	   created,	   for	  example	   1,2-­‐dioleyl-­‐3-­‐trimethylammonium	   propane	   (DOTAP),	   1,2-­‐dimyristoyl-­‐trimethyl-­‐ammonium	   propane	   (DMTAP)	   and	   dimethyldioctadecylammonium	  bromide	   (DDA).	   A	   common	   property	   for	   all	   phospholipids	   is	   that	   they	   are	  amphiphilic.	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Figure	  2.	  A:	  Examples	  of	  lipids	  with	  different	  properties:	  1,2-­‐dioleyl-­‐3-­‐trimethylammonium	  propane	  
(DOTAP),	   with	   a	   positively	   charged	   headgroup	   and	   unsaturated	   alkyl	   chains;	  
dimyristoylphosphatidylglycerol	  (DMPG),	  with	  a	  negatively	  charged	  headgroup	  and	  saturated	  alkyl	  
chains	   and	   1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	   (POPC),	   with	   a	   zwitterionic	  
headgroup	  and	  one	  unsaturated	  and	  one	  saturated	  alkyl	  chain.	  B:	  A	  liposome	  is	  a	  spherical	  bilayer	  
structure	   consisting	   of	   lipids	   with	   a	   cylindrical	   geometry.	   C:	   Spherical	   or	   elongated	   micellar	  
structures	   consists	   of	   lipids	   with	   a	   conical	   geometry.	   D:	   Lipodisks,	   bilayer	   segments	   with	   edges	  
stabilized	  by	  micelle-­‐forming	  lipids,	  can	  be	  formed	  by	  mixing	  bilayer-­‐	  and	  micelle-­‐forming	  lipids	  at	  
certain	  ratios.	  In	   an	   aqueous	   environment,	   amphiphilic	  molecules	   such	   as	  phospholipids	   self-­‐assemble	   into	   different	   types	   of	   molecular	   assemblies	   where	   the	   hydrophobic	  parts	   face	   each	   other	   and	   form	   a	   protected	   compartment	  with	   the	   hydrophilic	  parts	  facing	  the	  aqueous	  solvent.[26]	  Such	  self-­‐assembled	  amphiphilic	  structures	  exist	  in	  an	  equilibrium	  state,	  meaning	  that	  they	  are	  not	  definite	  and	  constant	  but	  often	  fluid	  in	  the	  sense	  that	  their	  size	  and	  shape	  is	  not	  sharply	  defined	  but	  rather	  a	   distribution.[27]	  The	  most	   energetically	   favorable,	   and	   therefore	  most	   likely,	  structures	   adopted	   by	   amphiphiles	   depend	   on	   concentration	   and	  physicochemical	   properties	   of	   the	   amphiphiles	   as	   well	   as	   on	   environmental	  factors	   such	   as	   the	   temperature,	   the	   ionic	   strength	   and	   the	   pressure,	   although	  the	   latter	   effect	   is	   generally	   small.[26]	   Among	   the	   properties	   of	   amphiphilic	  molecules	   the	  geometry	   is	  also	  of	  particular	   interest	  as	   it	  affects	   the	  molecular	  packing	  and	  thus	  the	  type	  of	  structures,	  or	  mesophases,	  that	  are	  formed.	  There	  are	  essentially	  two	  basic	  structures:	  micelles	  and	  bilayers.	  Micelles	  are	  spherical	  or	   cylindrical	   structures	   with	   a	   hydrocarbon	   core	   and	   a	   surface	   consisting	   of	  hydrophilic	   groups	   (Figure	   2C).	   Amphiphiles	  with	   a	   conical	   geometry	   i.e.	   with	  large	   headgroup	   area,	   often	   due	   to	   a	   charged	   or	   bulky	   headgroup,	   and	   a	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comparatively	   small	   hydrophobic	   tail	   tend	   to	   form	   micellar	   structures.	  Amphiphiles	   with	   a	   tail	   region	   that	   is	   large	   compared	   to	   the	   headgroup,	   for	  example	   when	   the	   hydrophobic	   tail	   consist	   of	   two	   alkyl	   chains,	   have	   a	   more	  cylindrical	  geometry,	  and	  will	  tend	  to	  form	  bilayer	  structures	  (Figure	  2B).[27]	  So	  called	   lipid	   bilayers	   consist	   of	   two	   layers	   of	   amphiphiles	   assembled	   with	   the	  hydrocarbon	   chains	   facing	   each	   other,	   thereby	   protected	   from	  thermodynamically	   unfavorable	   interactions	   with	   the	   aqueous	   solution	   by	   the	  hydrophilic	   headgroups.	   Both	   bilayers	   and	   micelles	   can	   form	   large	  interconnected	   structures,	   crystalline	   phases,	   or	   remain	   as	   separate	   entities,	  thereby	   forming	  particles.	  Such	  particles	  are	  of	   interest	   for	  many	  types	  of	  drug	  delivery	  applications	  and	  for	  vaccine	  delivery	  purposes.[28]	  	  One	  type	  of	  lipid-­‐based	  particle	  commonly	  encountered	  is	  the	  vesicle,	  also	  called	  liposome.	  In	  this	  case,	  the	  energetically	  unfavorable	  outer	  edges	  of	  planar	  bilayer	  sheets	  are	  eliminated	  by	  forming	  a	  hollow	  sphere.	  The	  sphere	  consists	  of	  either	  a	  single	  or	  multiple	  phospholipid	  bilayers	  and	  liposomes	  are	  accordingly	  classified	  as	  either	  unilamellar	  or	  multilamellar.	  Liposomes	  where	  discovered	  in	  1965	  by	  Bangham	  et	  al.	  and	  in	  the	  1970’s	  they	  were	  for	  the	  first	  time	  explored	  for	  drug	  delivery	  purposes	  and	  as	  immunological	  adjuvants.[29-­‐31]	  Liposomes	  have	  since	  been	   extensively	   explored	   as	   vaccine	   vectors,	   with	   several	   examples	   being	   in	  commercial	  use	  and	  clinical	   trials.[13,	  32,	  33]	  Particles	  which	  contain	  elements	  of	  both	  micelles	  and	  bilayers	  may	  form	  if	  conical	  and	  cylindrical	  lipids	  are	  mixed.	  One	   such	   example	   of	   direct	   relevance	   to	   this	   thesis,	   is	   the	   lipodisk,	  which	  was	  first	   described	   by	  Edwards	   et	   al.	   in	   1997.[34]	   Lipodisks	   are	   flat,	   single	   bilayer	  disks,	  comprising	  bilayer-­‐forming	   lipids	  with	  micelle-­‐forming	   lipids	  eliminating	  the	   energetically	   unfavorable	   contribution	   from	   the	   high-­‐curvature	   edges	  (Figure	   2D).	   Lipodisks	   have	   been	   used	   as	   membrane	   mimics	   and	   for	   drug	  delivery	   purposes	   but	   until	   now	   they	   have,	   to	   the	   best	   of	   our	   knowledge,	   not	  been	  considered	  for	  use	  as	  vaccine	  vectors.[35-­‐37]	  Other	  phases	  that	  have	  been	  considered	  for	  vaccine	  delivery	  include	  various	  types	  of	  emulsions	  and	  ISCOMs;	  immunostimulating	   complexes,	   comprising	   saponins	   from	   the	   Quillaia	  
saponaria	  tree,	   cholesterol	   and	   phospholipids,	   which	   form	   hollow	   cage-­‐like	  nanoparticles	   when	   mixed	   at	   a	   certain	   stoichiometry.[38-­‐41]	   However,	   such	  formulations	  have	  so	  far	  not	  been	  considered	  within	  this	  work.	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Lipid	  particles	  for	  mucosal	  vaccine	  delivery	  Lipid	   particles	   have	   attracted	   considerable	   interest	   as	   carriers	   for	   mucosal	  vaccine	  delivery	  for	  a	  number	  of	  reasons.	  First	  of	  all,	  the	  membrane	  composition	  is	  easily	  adjustable	  and	  membrane	  constituents	  can	  be	  synthetic	  or	  sourced	  from	  vastly	   different	   organisms,	   which	   invites	   to	   biomimicry.	   Thus,	   attempts	   have	  been	  made	   to	   enhance	   the	   immunogenicity	   of	   a	   lipid	   formulation	   by	   choosing	  membrane	   components	   with	   archaeal,	   bacterial	   or	   viral	   origins.[42-­‐48]	  Conversely,	   by	   choosing	   endogenous	   lipids,	   vectors	   can	   be	   made	   entirely	  innocuous:	  biodegradable,	  non-­‐toxic	  and	  non-­‐immunogenic.[25,	  49]	  Oftentimes,	  highly	  immunogenic	  formulations	  are	  also	  toxic,	  and	  creating	  a	  formulation	  that	  is	   effective	   without	   unwanted	   side	   effects	   is	   a	   challenge.	   One	   may	   therefore	  attempt	   to	   systematically	   address	  which	  particular	   physicochemical	   properties	  are	  at	  the	  root	  of	  the	  immunogenic	  effect	  to	  be	  able	  to	  create	  formulations	  with	  the	  desired	  properties	  but	  without	  toxic	  constituents.	  	  An	   advantage	   of	   lipid-­‐based	   vaccine	   formulations	   is	   that	   the	   physicochemical	  properties	  of	  the	  lipid	  particles	  are	  vastly	  adjustable.	  The	  membrane	  properties	  can	  be	  tuned	  by	  altering	  the	  lipid	  composition:	  the	  surface	  charge	  of	  the	  particles	  is	  largely	  affected	  by	  the	  characteristics	  of	  the	  lipid	  headgroup,	  and	  the	  degree	  of	  hydrophilicity	   can	   be	   tuned	   by	   addition	   of	   polymers	   such	   as	   poly(ethylene	  glycol)	  (PEG).[10,	  50]	  The	  headgroup	  charge,	  along	  with	  the	  length	  and	  degree	  of	  saturation	   of	   the	   alkyl	   chains	   of	   the	   tails,	   further	   influences	   the	   transition	  temperature	  of	   the	   lipids,	  which	   in	   turn	  determines	  whether	  a	   lipid	  membrane	  exists	   in	  gel-­‐	  or	   fluid-­‐phase	  at	  a	  certain	   temperature.	  Moreover,	   if	  a	  membrane	  consists	   of	   a	   mixture	   of	   lipids,	   phase	   separations	   can	   occur,	   resulting	   in	  heterogeneous	  distribution	  of	  different	  lipids.	  The	  stability	  of	  a	  membrane,	  i.e.	  its	  resistance	  to	  degradation,	  is	  affected	  by	  its	  fluidity	  and	  permeability	  as	  well	  as	  its	  bending	  rigidity,	  which	  are	   in	   turn	   influenced	  by	  the	  same	   lipid	  characteristics.	  Incorporation	  of	  cholesterol	  (Chol)	  is	  a	  common	  way	  to	  modulate	  the	  membrane	  permeability,	   fluidity	   and	   rigidity,	   which	   influence	   the	   liquid-­‐to-­‐gel	   phase	  transition	   temperature	  and	  stability.[28,	  51]	  Liposome	  size	  and	   lamellarity	   can	  be	   tailored	   by	   altering	   the	   manufacturing	   method;	   for	   lipodisks,	   the	   size	   is	  affected	  by	  both	  method	  and	  composition.[51,	  52]	  	  An	   inherent	   property	   of	   lipid	   particles,	   which	   makes	   them	   useful	   as	   antigen	  carriers,	  is	  that	  they	  contain	  both	  hydrophobic	  and	  hydrophilic	  regions,	  allowing	  for	   a	   variety	   of	   coupling	   strategies.	   Hydrophobic	   peptides	   or	   proteins	   can	   be	  incorporated	   into	   the	   hydrocarbon	   center	   of	   bilayers	   or	   micelles,	   while	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hydrophilic	   molecules	   can	   be	   coupled	   to	   the	   surface	   of	   lipid	   particles	   or	  encapsulated	   in	   the	   aqueous	   core	   of	   liposomes	   (see	   Figure	   3C).	   Surface	  association	  can	  take	  place	  by	  covalent	  attachment	  or	  spontaneous	  association	  of	  the	   antigen	   to	   the	   surface	   through	   adsorption	   or	   electrostatic	   interaction	   or	  alternatively,	   the	  antigen	  can	  be	  attached	   to	  a	  hydrophobic	  anchor	   that	   inserts	  into	   the	   particle.	   In	   cases	   where	   the	   lipid	   particles	   are	   included	   in	   a	   vaccine	  formulation	  solely	  as	  an	  adjuvant,	  they	  may	  simply	  be	  co-­‐administered	  with	  the	  antigen.	  	  With	  the	  possibility	  to	  tailor	  both	  preparation	  method	  and	  composition,	  as	  well	  as	  ways	  of	   incorporating	  antigen	   in	   the	   formulation,	   there	  are	  virtually	  endless	  possibilities	   in	   the	   production	   of	   lipid	   structures	   with	   varying	   properties.	  However,	   it	   still	   remains	   to	   be	   understood	   why	   the	   immune	   response	   is	  modulated	  differently	  by	  different	  liposomal	  formulations,	  and	  which	  properties	  that	  are	  decisive	   for	   the	  outcome.	  This	   is	  a	  particularly	  challenging	  task	  as	   it	   is	  inherently	  difficult	  to	  isolate	  the	  contribution	  of	  different	  properties,	  as	  changing	  one	   property	   usually	   influences	   one	   or	   several	   others.	   For	   instance,	   when	  varying	  the	  surface	  charge	  by	  altering	  the	  lipid	  composition	  one	  may	  inherently	  affect	  other	  properties,	   such	  as	  membrane	   fluidity	  and	  rigidity,	  as	  well	  as	   their	  resistance	   to	   enzymatic	   degradation,	   etc.	   Hence,	   it	   may	   be	   difficult	   to	   directly	  assess	  the	  influence	  of	  changing	  different	  physicochemical	  properties	  of	  carriers	  on	   the	   immune	   response.	   Nevertheless,	   attempts	   have	   been	   made	   to	  systematically	   study	   the	   influence	   of	   physicochemical	   properties	   of	   liposomes	  used	   in	   mucosal	   vaccines	   against	   infectious	   diseases	   on	   immunogenicity,	   as	  summarized	  in	  further	  detail	  below,	  starting	  with	  surface	  charge	  and	  followed	  by	  sections	   addressing	   size	   and	   lamellarity,	   resistance	   to	   degradation,	   rigidity,	  
antigen	  localization	  and	  modifications	  to	  increase	  bioavailability.	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Figure	   3.	   A:	   The	   effect	   of	   altered	   surface	   charge	   on	   liposome	   function	   has	   been	   extensively	  
examined.[53,	  54]	  B:	  The	  lipid	  composition	  is	  critically	  influencing	  the	  immune	  response.[55]	  C:	  Also	  
the	   localization	   of	   the	   antigen,	   on	   or	   inside	   the	   liposome,	   plays	   an	   important	   role	   in	   shaping	   the	  
immune	   response	   to	   the	   vaccine.	   There	   are	   several	   modes	   of	   antigen	   association	   to	   liposomes.	  
Firstly,	  antigens	  may	  be	  encapsulated	  in	  the	  aqueous	  core	  or	  they	  could	  be	  linked	  to	  the	  surface	  via	  
covalent	  attachment.	  Alternatively,	  a	  hydrophobic	  anchor	  can	  be	  used	   to	  attach	   the	  antigen	   to	   the	  
surface	   via	   adsorption	   or	   through	   electrostatic	   interactions	   with	   lipids	   of	   opposite	   charge.	   For	  
proteins	   with	   a	   hydrophobic	   region	   one	   may	   even	   successfully	   insert	   these	   in	   the	   liposome	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membrane.	  The	  liposome	  may	  also	  be	  used	  as	  an	  immunoenhancer	  simply	  by	  admixing	  the	  antigen	  
and	  the	  liposomes.	  D:	  Only	  few	  studies	  have	  addressed	  the	  impact	  of	  size	  or	   lamellarity.[43,	  56]	  E:	  
Modifications	  of	  liposomes	  to	  increase	  their	  immunoenhancing	  effect	  can	  be	  done	  through	  attaching	  
PAMPs,	   such	   as	   lipid	   A	   (in	   inset,	   see	   section	   2.2	   for	   further	   information),	   or	   through	   specific	  
targeting	   strategies	   using	   cell-­‐specific	   antibodies	   (anti-­‐CD103	   or	   -­‐DEC205).[46,	   57]	   F:	   Other	  
modifications,	  including	  addition	  of	  poly(ethylene	  glycol)	  (PEG)	  or	  different	  polymer	  coatings,	  that	  
increase	   the	   liposome	   penetration	   of	   the	   mucosal	   barrier	   or	   to	   increase	   liposome	   resistance	   in	  
biological	  fluids,	  have	  also	  been	  developed	  (see	  section4.6).[58]	  
 Surface	  charge	  4.1One	   of	   the	   most	   commonly	   explored	   parameters	   in	   the	   context	   of	   mucosal	  vaccine	   delivery	   is	   the	   surface	   charge	   of	   the	   liposome	   (Figure	   3A),	   which	   is	  generally	  assessed	  by	  the	  zeta	  potential,	  a	  measure	  of	  the	  electrostatic	  potential	  at	  the	  limit	  of	  what	  is	  called	  the	  diffuse	  electric	  double-­‐layer	  that	  surrounds	  the	  particle	   (see	   section	   5.4).	   The	  magnitude	   of	   the	   zeta	   potential	   depends	   on	   the	  concentration	  of	  ions	  within	  the	  double	  layer	  but	  also	  other	  factors,	  such	  as	  the	  ionic	  strength	  and	  pH	  of	  the	  dispersion	  medium.	  This	  must	  be	  kept	  in	  mind	  when	  comparing	  zeta	  potential	  values	  reported	  in	  different	  studies	  and	  under	  different	  conditions,	   as	   well	   as	   when	   considering	   the	   relevance	   of	   this	   parameter	   in	   in	  
vitro	  and	  in	  vivo	  studies.	  	  	  Because	  the	  cell	  surface	  as	  well	  as	  the	  mucus	  coating	  of	  the	  mucous	  membrane	  is	  negatively	  charged,	  positively	  charged	  liposomes	  will	  generally	  exhibit	  stronger	  interactions	  with	  the	  cell	  membrane	  as	  well	  as	  an	  increased	  mucoadhesion.[14,	  25]	   The	   latter	   leads	   to	   reduced	   clearance	   rate,	   i.e.	   slower	   removal	   from	   the	  mucous	   membranes.	   This	   may	   be	   beneficial	   for	   antigen	   delivery	   as	   both	  increased	  interactions	  with	  the	  cell	  membrane	  and	  prolonged	  exposure	  time	  of	  the	   antigen	   at	   the	   mucosal	   surface,	   are	   thought	   to	   lead	   to	   increased	   cellular	  uptake	   of	   antigen	   and	   stronger	   immune	   responses.[59,	   60]	   Indeed,	   cationic	  liposomes	  were	  found	  to	  effectively	  deliver	  antigen	  to	  both	  mucus	  and	  APCs	  as	  shown	  in	  an	   in	  vitro	  model	  of	  the	  airway	  epithelium	  with	  liposomes	  made	  with	  distearoylphosphatidylcholine	  (DSPC)/trehalose	  6,6-­‐dibehenate	  (TDB)	  (neutral)	  and	  DSPC/TDB/DDA	  (positive)	  with	  varying	  amounts	  of	   the	  positively	  charged	  DDA.[61]	  Moreover,	  cationic	  liposomes	  consisting	  of	  DOTAP/Chol,	  DMTAP/Chol	  or,	   most	   prominently,	   the	   polycationic	   sphingolipid	   ceramide	   carbamoyl-­‐spermine	   (CCS)	   and	   Chol	   were	   shown	   to	   effectively	   stimulate	   systemic	   and	  mucosal	  humoral	  and	  cellular	  immune	  responses	  after	  intranasal	  immunizations	  in	  mice.[53]	  In	  contrast,	  neutral	  liposomes	  with	  dimyristoylphosphatidylcholine	  (DMPC)	   or	   anionic	   liposomes	   with	   DMPC/dimyristoylphosphatidylglycerol	  (DMPG)	   were	   comparably	   ineffective	   as	   immunogens.[53]	   While	   a	   positive	  charge	  appeared	  to	  increase	  the	  immunogenicity	  of	  liposomes	  in	  these	  cases,	  this	  may	   not	   always	   be	   true.	   In	   fact,	   there	   are	   scientific	   reports	   suggesting	   that	  negatively	  charged	  liposomes	  are	  more	  immunogenic	  than	  both	  zwitterionic	  and	  positively	   charged	   liposomes	   and	   it	   has	   even	   been	   postulated	   that	   anionic	  liposomes	  could	  exert	  an	  immunosuppressive	  effect	  on	  alveolar	  macrophages	  (a	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type	  of	  macrophage	  found	  in	  the	  alveoli	  of	  the	  lungs,	  see	  section	  2),	  and	  in	  this	  way	   promote	   an	   enhanced	   humoral	   immune	   response.[54,	   62-­‐65]	   Hence,	   it	  appears	   that	   several	   mechanisms	   can	   be	   modulated	   by	   the	   charge	   of	   the	  liposome.	  In	  particular,	  the	  influence	  of	  charge	  on	  immunogenicity	  may	  be	  highly	  dependent	  on	  the	  administration	  route,	  where	  different	  microenvironments	  with	  varying	  electrostatic	  properties	  may	  be	  encountered.	  	  
 Size	  and	  lamellarity	  4.2A	   broad	   range	   of	   unilamellar	   and	   multilamellar	   liposomes	   with	   varying	   sizes	  (Figure	  3D)	  has	   been	  proposed	   for	   vaccine	  delivery	   and	   the	  different	   particles	  have	   been	   found	   to	   induce	   different	   effects	   following	   mucosal	   immunization.	  However,	   the	   influence	   of	   these	   parameters	   on	   liposome	   immunogenicity	   has	  rarely	   been	   systematically	   investigated	   and	   unfortunately	   the	   degree	   of	  multilamellarity	  is	  not	  routinely	  reported.	  Lamellarity	  is	  typically	  assessed	  using	  techniques	   such	   as	   nuclear	   magnetic	   resonance	   spectroscopy,	   cryogenic	  transmission	   electron	   microscopy	   or	   small-­‐angle	   X-­‐ray	   scattering	   [51],	   which	  may	   still	   be	   considered	   specialized	   techniques	   that	   are	   not	   always	   readily	  available.	   The	   few	   studies	   reporting	   on	   the	   effects	   of	   lamellarity	   on	  immunogenicity	  show	  inconclusive	  results.	  Towards	  understanding	  the	  effect	  of	  size	  and	   lamellarity,	  a	  comparative	  study	  between	  unilamellar	   liposomes	  made	  from	  archaeal	  polar	  lipids	  (archaeosomes)	  with	  an	  average	  diameter	  of	  100	  nm	  and	   large	   multilamellar	   particulate	   aggregates	   clearly	   indicated	   better	  immunogenicity	  for	  the	  multilamellar	  aggregates.[43]	  However,	  it	  is	  noteworthy	  that	   not	   only	   the	   size,	   but	   also	   the	   lipid	   structure	   was	   different	   between	   the	  unilamellar	   and	   multilamellar	   constructs	   in	   this	   example.	   Another	   study	  reported	   that	   oral	   administration	   of	   a	   “double	   liposome”,	   consisting	   of	   small	  (~250	   nm)	   liposomes	   made	   from	   SoyPC,	   dipalmitoylphosphatidylcholine	  (DPPC),	   Chol	   and	   stearylamine	   encapsulated	   into	   a	   bigger	   (1	   to	   10	   µm)	   outer	  liposome	   made	   from	   DMPC	   and	   DMPG,	   was	   found	   only	   marginally	   more	  immunogenic	   than	   small	   liposomes.[56]	   Additionally,	   a	   study	   using	   liposomes	  made	   from	   DPPC,	   DDA	   and	   Chol	   with	   sizes	   ranging	   from	   70	   to	   1000	   nm	   for	  intranasal	  immunization	  of	  mice	  similarly	  showed	  no	  significant	  effect	  of	  size	  on	  immunogenicity.[66]	  	  Constructing	   homogeneous	   liposomes	   of	   controlled	   lamellarity	   is	   technically	  challenging	   and	   various	   degrees	   of	   multilamellar	   constructs	   may	   co-­‐exist,	  making	   interpretations	  of	  experimental	  results	  difficult.	  Recent	  advances	   in	  the	  production	   of	   tightly	   size-­‐controlled	   liposomes	   may	   allow	   for	   more	   accurate	  comparisons	   of	   the	   influence	   of	   size,	   lamellarity	   and	   overall	   structure	   in	   the	  future.[67]	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 Liposome	  resistance	  to	  degradation	  4.3The	   lipid	   composition	   (Figure	   3B)	   is	   known	   to	   influence	   the	   stability,	   i.e.	  resistance	  to	  degradation,	  of	  the	  liposome;	  a	  more	  stable	  formulation	  might	  lead	  to	   a	   larger	   amount	   of	   bioavailable	   antigen	   and	   potentially	   also	   to	   a	   depot,	   i.e.	  slow	   release,	   effect.	   Han	   et	   al.	   made	   liposomes	   from	   various	   combinations	   of	  Chol,	   DPPC,	   Dipalmitoylphosphatidylserine	   (DPPS)	   and	  distearoylphosphatidylcholine	   (DSPC)	   and	   found	   that	   certain	   combinations	  decreased	   leakage	   of	   encapsulated	   carboxyfluorescein	   in	   different	   solutions	  simulating	   conditions	   in	   the	   gastrointestinal	   tract.[47]	   Liposomes	   with	   DSPC,	  having	   a	   higher	   transition	   temperature,	   were	   more	   stable	   in	   vitro	   and	   likely	  protected	   antigen	   better	   from	   degradation	   in	   the	   gastrointestinal	   tract.[47]	   As	  aforementioned,	   using	   archaeal	   lipids,	   liposomes	   can	   be	   made	   more	  immunogenic	   and	   archaeosomes	   were	   found	   considerably	   more	   potent	   than	  liposomes	  made	  with	  Egg	  phosphatidylcholine	   (EPC)/Chol	  at	   inducing	  antigen-­‐specific	   IgG	   and	   IgA	   antibodies	   following	   oral	   administration	   in	   a	   mouse	  model.[42]	   This	  was	   attributed	   by	   the	   authors	   to	   an	   increased	   stability	   in	   the	  gastrointestinal	  tract	  and	  to	  the	  fact	  that	  the	  archaeosomes	  were	  better	  retained	  in	  the	  intestine.	  [42]	  However,	  the	  difference	  may	  also	  partly	  reflect	  the	  fact	  that	  the	  archaeosomes	  were	  negatively	  charged	  while	  the	  EPC/Chol-­‐liposomes	  were	  neutral	   and,	   as	   discussed	   in	   section	   4.1,	   negatively	   (or	   positively)	   charged	  liposomes	  are	  generally	  more	  immunogenic	  than	  neutral	  ones.	  
 Liposome	  rigidity	  4.4Parameters	   that	   affect	   the	   stability	   to	   degradation	   of	   liposomal	   formulations	  generally	   also	   influence	   the	   membrane	   bending	   rigidity,	   or	   deformability.	  Experimentally	   quantifying	   membrane	   rigidity	   of	   nanoscopic	   lipid	   vesicles	   is	  however	  not	   trivial	   and	   the	   role	  of	   liposome	   rigidity	   in	   the	   context	  of	  mucosal	  vaccine	   delivery	   has	   not	   been	   expressly	   studied.	   However,	   this	   property	   has	  been	  ascribed	  an	  increased	  importance	  in	  cellular	  uptake.[68]	  	  Theoretical	  modeling	  of	   cellular	  uptake	  has	   shown	   that	   the	  energy	   required	   to	  achieve	   full	   wrapping	   of	   the	   particle	   by	   the	   membrane	   is	   higher	   for	   softer	  particles	   and	   that	   they	   require	   higher	   adhesion	   energies	   to	   be	   successfully	  internalized	   compared	   to	   rigid	   particles.[69,	   70]	   Soft	   particles	   are	   therefore	  more	   likely	   to	   remain	   partially	  wrapped,	   essentially	   trapped	   at	   the	  membrane	  surface.[69,	   71]	   It	   has	   been	   confirmed	   experimentally	   that	   rigid	   particles	   are	  taken	  up	  to	  a	  larger	  extent	  than	  soft	  ones.[71,	  72]	  Conversely,	  Allen	  et	  al.	  showed	  that	  by	   increasing	   the	  content	  of	   lipids	  hypothesized	   to	   increase	   the	   rigidity	  of	  the	   tested	   liposome	   formulations,	   the	   uptake	   by	   macrophages	   decreased.[73]	  These	   indications	   that	   membrane	   rigidity	   is	   a	   key	   factor	   governing	   liposome	  uptake	  prompted	  us	  to	  investigate	  if	  and	  how	  this	  parameter	  influences	  antigen	  processing	  by	  APCs	  (Paper	  II).	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 Antigen	  localization	  4.5There	  are	  many	  ways	  of	   incorporating	  antigens	   into	   liposomes.	  This	   raises	   the	  question	  whether	  some	  strategies	  are	  more	  effective	  than	  others	   in	  the	  context	  of	  optimizing	  the	  immunogenicity	  of	  the	  liposome	  formulation.	  Antigens	  can	  be	  hosted	  in	  the	  aqueous	  core	  of	  the	  liposome,	  inserted	  into	  the	  hydrophobic	  part	  of	  the	   membrane	   or	   bound	   to	   the	   surface	   by	   covalent	   bonds	   or	   intermolecular	  forces	  (Figure	  3C,	  Section	  4).	  Hence,	  a	  plethora	  of	  combinations	  exist	  and	  those	  could	   be	   used,	   in	   combination	   with	   various	   lipid	   compositions,	   to	   enhance	  resistance	  against	  antigen	  degradation	  or	  to	   facilitate	  antigen	  uptake.	  Thus,	   the	  liposome	  formulation	  may	  be	  tailored	  for	  specific	  needs	  and	  purposes.	  If	  an	  oral	  vaccine	   is	   to	   be	   designed,	   one	  may	  hypothesize	   that	   encapsulating	   the	   antigen	  inside	   the	   liposomes	   is	   an	  effective	   strategy	   to	  prevent	  enzymatic	  degradation.	  However,	   by	   hiding	   the	   antigen	   in	   the	   liposome,	   the	   immunogenicity	   may	   be	  compromised	  because	   the	  antigen	  will	  not	  be	   immediately	  accessible	   for	  APCs.	  Therefore,	   choosing	  how	   to	  physically	   incorporate	   the	   antigen	   in	   the	   liposome	  may	   have	   critical	   consequences	   on	   the	   immune	   response.	   Unfortunately,	   such	  aspects	  have	  not	  been	  addressed	  in	  a	  systematic	  manner	  thus	  far.	  Studies	  report	  that	   when	   administered	   orally,	   encapsulated	   antigen	   may	   more	   effectively	  stimulate	  local	  IgA	  and	  serum	  IgG	  antibody	  responses	  compared	  to	  when	  soluble	  antigen	   is	   admixed	   with	   the	   liposomes.[74,	   75]	   On	   the	   other	   hand,	   following	  intranasal	   administration,	   a	   mixture	   of	   antigen	   and	   liposomes	   has	   been	   quite	  effective	  even	  compared	  to	  liposome-­‐encapsulated	  antigen.[53,	  63]	  Interestingly,	  liposomes	   have	   been	   found	   to	   exert	   an	   immuno-­‐enhancing	   effect	   even	   when	  administered	   48	   hours	   prior	   to	   the	   antigen.[63]	   Furthermore,	   surface-­‐bound	  antigen	   has	   been	   found	   to	   be	   more	   immunogenic	   than	   encapsulated	   antigen	  following	   intranasal	   immunization.[64]	   These	   observations	   suggest	   that	   the	  intranasal	   route	   is	   less	   sensitive	   to	   antigen	   degradation	   compared	   to	   the	   oral	  route.	   Thus,	   depending	   on	   the	   route	   of	   administration,	   it	   seems	   clear	   that	  antigens	   may	   or	   may	   not	   be	   immunogenic	   when	   exposed,	   and	   for	   many	  formulations	   it	  may,	   in	   fact,	  be	  advantageous	  to	  have	  a	  combination	  of	  surface-­‐bound	  and	  encapsulated	  antigens.	  This	  may	  also	  apply	  to	  molecular	  adjuvants;	  it	  was	   found	  that	  cholera	   toxin	  B-­‐subunit	   (CTB)	  adjuvant	  bound	  to	   the	  surface	  of	  the	   liposome	   was	   more	   effective	   compared	   to	   when	   encapsulated	   in	   the	  liposome.[76]	   Furthermore,	   it	   has	   been	   observed	   that	   by	   altering	   the	   lipid-­‐to-­‐antigen	   ratio,	   the	   systemic	   and	   mucosal	   as	   well	   as	   the	   humoral	   and	   cellular	  immune	  responses	  can	  be	  differentially	  induced.[53,	  77]	  Thus,	  it	  is	  likely	  that	  the	  immune	   response	   following	   liposome	  administration	   is	   susceptible	   not	   only	   to	  the	   choice	   of	   antigen	   and	   adjuvant	   but	   also	   to	   their	   relative	   proportions	   and	  localization	  in	  the	  liposome.	  
 Modifications	  to	  increase	  bioavailability	  4.6The	  microenvironment	  at	  mucosal	  surfaces	  often	  promotes	  a	  high	  clearance	  rate	  of	   liposomes.	  Therefore,	  various	  strategies	  have	  been	   tested	   to	  enhance	  mucus	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penetration	  or	  to	  increase	  antigen-­‐carrying	  liposome-­‐to-­‐cell	  membrane	  adhesion	  in	  order	  to	  increase	  the	  bioavailability	  of	  the	  vaccine	  antigens	  (Figure	  3F).	  Layer-­‐by-­‐layer	  deposition	  of	  polyelectrolytes	  onto	  the	  liposomes,	  for	  example,	  has	  been	  used	  as	  a	  liposome-­‐stabilizing	  approach	  which	  resulted	  in	  higher	  specific	  IgA	  and	  IgG	  antibody	  levels	  as	  well	  as	  an	  increased	  T	  cell	  response.[78]	  Poly-­‐vinyl	  alcohol	  or	  chitosan	  have	  been	  tested	  to	  enhance	  bioadhesive	  properties	  of	  the	  liposomes	  and	  it	  has	  been	  observed	  that	  chitosan-­‐loaded	  liposomes,	   indeed,	   increased	  IgG	  antibody	  responses.[79]	  Chitosan	  is	  a	  positively	  charged	  polysaccharide	  that	  can	  form	   strong	   electrostatic	   interactions	   with	   cell	   surfaces	   and	   mucus	   and,	  therefore,	   increase	   retention	   time	   and	   facilitate	   interactions	   between	   the	  liposome	   and	   APCs	   in	   the	   mucous	   membrane.[80]	   Additionally,	   chitosan	   can	  transiently	   open	   tight	   junctions	   between	   epithelial	   cells	   to	   allow	   for	  transmucosal	   transport.[81,	   82]	   Chitosan-­‐modification	   of	   liposomes	   is	  accordingly	  a	  popular	  strategy	  for	  delivery	  of	  peptidic	  antigens.[58,	  79,	  83,	  84]	  In	  fact,	   chitosan-­‐coated	   liposomes	   have	   been	   shown	   to	   give	   better	   serum	   IgG	  antibody	   levels	   compared	   to	   other	   bioadhesive	   polymers,	   such	   as	   hyaluronic	  acid-­‐	   or	   carbopol-­‐coated	   liposomes,	   and	   host	   better	   immunogenicity	   than	  uncoated	  negative,	  neutral	  or	  positively	  charged	  liposomes.[84]	  	  	  Considerable	  attention	  has	  been	  given	   to	   studying	  how	   liposomes	  are	   retained	  by	  and/or	  taken	  up	  across	  the	  mucous	  membranes.	  Liposome	  interactions	  with	  the	   intestinal	   mucosa	   have	   been	   studied	   in	   vivo	   and	   ex	   vivo	   as	   well	   as	   using	  various	   in	   vitro	   models.[42,	   78,	   85,	   86]	   The	   latter	   models	   have	   addressed	  whether	  passage	  of	   liposomes	  through	  the	  tight	   junctions	  of	  epithelial	  cells	  can	  be	   achieved.	   Indeed,	   tight	   junctions	   were	   reported	   to	   be	   open	   when	   using	  PC/Chol-­‐liposomes	   or	   liposomes	   coated	   with	   extract	   from	   Tremella	  
fuciformis.[86]	   Enhanced	   immune	   responses	   was	   also	   observed	   with	   mucus-­‐penetrating	   liposomes	   made	   with	   poly(ethylene	   glycol)	   (PEG)	   or	   the	   PEG-­‐copolymer	  Pluronic.[58]	  Significantly	  higher	  specific	  IgA	  and	  IgG	  antibody	  levels	  were	   found	  with	   PEGylated	   than	   non-­‐PEGylated	   liposomes.	  Modifications	  with	  PEG	   or	   Pluronic	   F127	   also	   proved	   useful	   in	   preventing	   liposome	   aggregation	  through	   steric	   stabilization	   to	   obtain	   small	   (<200	   nm)	   chitosan-­‐coated	  liposomes.	   In	   fact,	   these	   shielded	   chitosan-­‐coated	   and	   PEGylated	   liposomes	  yielded	   the	   highest	   functional	   serum	   antibody	   titers	   of	   all	   the	   formulations	  tested	  and	  the	  strongest	  IgA	  responses.[58]	  	  
 Cell-­‐targeting	  modifications	  4.7In	   the	   context	   of	   carriers	   for	   vaccine	   delivery,	   one	   of	   the	   most	   explored	  modifications	   is	  aimed	  at	   targeting	  the	  delivery	  of	   liposomes	  to	  subsets	  of	  cells	  that	   express	   a	   comparatively	   large	   amount	   of	   predefined	   receptors	   or	   binding	  sites.	   This	   is	   achieved	   by	   equipping	   the	   liposomes	   with	   various	   targeting	  elements	  to	  increase	  the	  amount	  of	  liposomes	  delivered	  to	  the	  target	  cell	  subset	  (Figure	   3E).	   For	   example,	   targeting	   components	  may	   be	   added	   to	   enhance	   the	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uptake	   by	   APCs	   or	   the	   penetration	   of	   the	   liposome	   through	   the	   mucous	  membrane.	   Additionally,	   the	   target	   receptor	   may	   be	   directly	   involved	   in	  immunological	   signaling	   and	   thereby	   enhancing	   the	   immunogenicity	   of	   the	  liposomes.	  	  	  APCs	  in	  the	  mucosal	  tissues	  have	  a	  high	  density	  of	  surface	  GM1	  and	  the	  strongly	  GM1-­‐ganglioside-­‐binding	  molecule	  CTB	  has	  been	  reported	  to	  enhance	  liposome	  immunogenicity.[46,	   87,	   88]	   DCs	   have	   similarly	   been	   targeted	   by	   use	   of	  mannosylated	  lipids	  or	  anti-­‐CD40	  antibody-­‐coated	  liposomes,	  which	  promoted	  a	  stronger	  immune	  response.[89,	  90]	  Another	  popular	  target	  on	  immune	  cells	  are	  TLRs,	   a	   type	   of	   pattern	   recognition	   receptor	   (PRR)	   used	   by	   phagocytes	   to	  recognize	  PAMPs,	   i.e.	  pathogen-­‐associated	  structural	  motifs.	  For	  instance,	  when	  monophosphoryl	   lipid	   A,	   acting	   through	   the	   TLR4	   receptors,	   was	   added	   to	  liposomes,	   their	   ability	   to	   stimulate	   the	   innate	   immune	   response	   was	  dramatically	   improved.[46,	  47,	  55]	  Other	  TLR	  agonists	  or	  Escherichia	  coli	  heat-­‐labile	   toxin	   (LT)	   have	   also	   been	   used	   in	   combination	   with	   liposomes	   as	  adjuvants.[44]	  Furthermore,	  linking	  CpG,	  which	  acts	  through	  TLR9	  signaling,	  or	  
Bordetella	  pertussis	   filamentous	   haemagglutinin,	   whose	   effects	   include	   binding	  to	   macrophage	   integrins,	   to	   liposomes	   have	   been	   found	   to	   enhance	  immunogenicity.[91,	   92]	   Targeting	   macrophages	   via	   C-­‐type	   lectins	   by	  galactosylation	   of	   liposomes	   resulted	   in	   higher	   specific	   IgA	   and	   IgG	   antibody	  levels	   compared	   to	   unmodified	   liposomes.[93]	   Another	   strategy	   to	   target	  macrophages	  is	  to	  incorporate	  PS.	  PS	  is	  naturally	  exposed	  on	  the	  surface	  of	  cells	  undergoing	   apoptosis	   and	   in	   this	   way	   liposomes	   containing	   PS	   may	   trigger	  phagocytosis	   by	   macrophages.	   Accordingly,	   it	   has	   been	   found	   that	   liposomes	  containing	   DPPS	   induced	   stronger	   IgA	   responses	   compared	   to	   formulations	  without	  DPPS.[55]	  Combinations	  of	  both	  DPPC/DMPG	  and	  DPPC/PS	  have	  been	  found	  effective	  at	  targeting	  liposomes	  to	  macrophages,	  and	  DPPC/DMPG	  was	  the	  only	   formulation	   to	   induce	   a	   significant	   antibody	   response	   following	   oral	  immunization.[74]	  	  	  Another	   strategy	   aims	   at	   making	   uptake	   through	   mucous	   membranes	   more	  effective	   by	   targeting	   M	   cells	   in	   the	   FAE,	   the	   thin	   epithelial	   cell	   layer	   that	   is	  responsible	   for	   antigen-­‐uptake	   from	   the	   luminal	   side.	   Accordingly,	   the	   lectin	  Agglutinin	   I	   from	   Ulex	   europaeus	   was	   shown	   to	   improve	   M	   cell-­‐mediated	  transport	   across	   the	   intestinal	   epithelium.[85,	   94,	   95]	   Similarly,	   liposomes	  functionalized	  with	   antibodies	   have	   been	   found	   to	   enhance	   binding	   to	  M	   cells,	  and	   as	   a	   result	   increased	   levels	   of	   IgG,	   Il-­‐2	   and	   IFN-­‐γ	   were	   shown	   following	  intranasal	  immunization.[57]	  	  Many	  strategies	  have	  been	  proposed	  to	  achieve	  cell-­‐targeting	  of	  liposomes,	  with	  varying	  degrees	  of	  improved	  function.	  A	  plethora	  of	  possibilities	  can	  be	  explored	  when	  it	  comes	  to	  targeting	  liposomes	  to	  the	  cells	  of	  the	  mucosal	  immune	  system.	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The	   combination	   of	   analytical	   tools	   for	   nanoparticle	   characterization	   with	  suitable	   in	   vitro	   and	   in	   vivo	   assays	   will	   greatly	   help	   identify	   the	   relative	  importance	  of	  liposome	  targeting	  and	  other	  properties	  discussed	  in	  this	  chapter	  and	  how	  they	  can	  influence	  the	  immune	  response.	  
 Concluding	  remarks	  	  4.8To	   conclude	   this	   chapter,	   it	   is	   clear	   that	   the	   design	   of	   a	   lipid-­‐based	   vaccine	  formulation	   is	   complex.	   Needless	   to	   say,	   it	   is	   important	   to	   consider	   all	   the	  properties	  of	  the	  formulation	  as	  well	  as	  the	  biological	  response.	  Thus,	  liposome	  size,	   lamellarity	  and	  surface	  charge	  as	  well	   as	   lipid	  composition	  and	  rigidity	  of	  the	   membrane	   can	   all	   influence	   the	   immune	   response	   following	   vaccination.	  Importantly,	   the	   choice	   of	   antigen,	   with	   its	   own	   inherent	   physicochemical	  properties,	  as	  well	  as	  the	  position	  of	  the	  antigen	  and	  any	  molecular	  adjuvant	  in	  the	   liposome	   critically	   affect	   the	   function	   of	   the	   formulation.	   Furthermore,	   the	  antigen/lipid	   ratio	   and	   properties	   of	   the	   added	   adjuvant	   are	   also	   important	  parameters	  that	  change	  the	  immunogenicity	  of	  the	  liposome.	  	  	  Despite	   this	   complexity,	   it	   is	   clear	   that	   lipid	   carriers	   can	  be	  used	   to,	   in	   a	   fairly	  controlled	  manner,	  modulate	   the	   immune	   response	   in	   a	  wide	  variety	  of	  model	  systems.	   It	   remains,	   however,	   to	   be	   elucidated	   by	   which	   mechanism	   their	  immunomodulation	   takes	   place	   and	   therefore,	   how	   to	   tune	   their	   properties	   in	  order	   to	   alter	   their	   effect.	  What	   are	   then	   the	   ideal	   properties	   of	   a	   strong	   and	  effective	  lipid-­‐based	  mucosal	  vaccine?	  This	  question	  is	  indeed	  difficult	  to	  answer,	  not	  only	  because	  the	  underlying	  mechanisms	  remain	  to	  be	  investigated,	  but	  also	  because	  there	  is	  currently	  no	  standardized	  procedure	  to	  assess	  the	  potential	  of	  lipid	  carriers	  in	  the	  context	  of	  vaccination.	  While	  specific	  aspects	  of	  the	  mode	  of	  action	   of	   liposomes	   are	   often	   studied,	   for	   example	   stability	   in	   simulated	  intestinal	   fluids,	  mucoadhesion	  and	  APC	  uptake,	  more	  systematic	  examinations	  of	  how	  different	  parameters	   influence	  different	  parts	  of	   the	  process	  remains	  to	  be	  seen.	  Especially	  the	  mechanism	  behind	  the	  immunostimulatory	  properties	  of	  liposomes,	  unrelated	  to	  their	  role	  as	  carriers,	  is	  poorly	  understood.	  However,	  the	  most	   fundamental	   step	   towards	  rational	  design	  of	   lipid-­‐based	  vaccine	  particles	  would	  be	  to	  develop	  a	  systematic	  protocol	  for	  measuring	  vaccination	  outcome	  as	  well	   as	   for	   the	   physicochemical	   characterization	   of	   the	   particles	   themselves.	  Moreover,	   identifying	   the	   immune	   responses	   that	   elicit	   mucosal	   protection	  would	  aid	  the	  rational	  design	  of	  effective	  mucosal	  vaccines.	  One	  aim	  of	  this	  thesis	  work	  is	  to	  take	  one	  step	  in	  this	  direction.	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  5
Experimental	  techniques	  The	   experimental	   techniques	   used	   in	   this	   work	   can	   be	   divided	   into	   two	  main	  categories:	   techniques	   used	   for	   physicochemical	   characterization	   of	   the	   lipid	  nanoparticles	   and	   techniques	   used	   for	   characterization	   of	   the	   elicited	   immune	  response,	   in	   particular	   uptake	   and	   processing	   by	   DCs.	   The	   former	   includes	  methods	   for	   quantification	   of	   protein	   content	   (Section	   5.1),	   particle	   size	  determination	   (Section	   5.2),	   examination	   of	   particle	   morphology	   (Section	   5.3)	  and	  surface	  charge	  (Section	  5.4).	  To	  characterize	  the	  elicited	  immune	  response,	  light	  microscopy	  is	  the	  technique	  of	  choice	  to	  follow	  particle	  uptake	  (Section	  5.5)	  while	   flow	   cytometry	   has	   been	   used	   to	   quantify	   antigen	   presentation	   (Section	  5.6).	  
 Fluorometry	  for	  protein	  quantitation	  5.1Fluorometry	  relies	  on	  the	  concept	  of	  fluorescence,	  which	  is	  commonly	  visualized	  using	  a	  Jablonski	  diagram,	  as	  seen	  in	  Figure	  4A.[96]	  In	  fluorescence,	  a	  molecule	  known	   as	   a	   fluorophore	   emits	   light	   when	   excited	   by	   incoming	   light	   of	  appropriate	   wavelength.	   Light	   of	   this	   wavelength	   consists	   of	   photons	   with	   an	  energy	   content	   that	   corresponds	   to	   the	   energy	   gap	   between	   the	   ground	   state	  (S0)	   and	   the	   next	   higher,	   excited,	   state	   (S1)	   of	   the	   fluorophore.	   When	   such	   a	  photon	  hits	   the	   fluorophore,	   the	  molecule	   is	  excited	   to	   the	  higher	  energy	  state.	  The	  higher	  energy	  state	  is	  not	  stable	  and	  hence	  the	  molecule	  rapidly	  returns	  to	  the	   ground	   state	   and	   in	   doing	   so	   light	   of	   a	   lower	   energy	   is	   emitted,	   as	   some	  energy	  is	  lost	  in	  thermal	  processes.[96]	  The	  energy,	  E,	  of	  a	  photon	  is	  given	  by:	  E = hcλ 	  where	   h	   is	   Planck’s	   constant,	   c	   is	   the	   speed	   of	   light	   and	   λ	   is	   the	   wavelength.	  Hence,	   the	   emitted	   lower	   energy	   photon	   will	   have	   a	   longer	   wavelength.	   The	  difference	   between	   the	   peak	   excitation	   wavelength	   and	   the	   peak	   emission	  wavelength	   of	   a	   certain	   fluorophore	   is	   termed	   Stoke’s	   shift.[97]	   A	   common	  method	   used	   to	   determine	   emission	   spectra	   for	   fluorophores	   and	   to	   generally	  quantify	  fluorescence	  is	  fluorometry.	  The	  basic	  components	  of	  a	  fluorometer	  are:	  a	   light	   source,	   a	   specimen	   chamber	   or	   sample	   holder	   and	   one	   or	   several	  photodectors	   such	   as	   photomultipliers	   and	   charge-­‐coupled	   device	   cameras.	  Additionally,	   there	   is	   commonly	   monochromators	   or	   filters	   to	   select	   specific	  excitation	  and	  emission	  wavelengths.	  	  	  	  Fluorometry	   can	   be	   used	   to	   determine	   protein	   content	   either	   by	   utilizing	  inherently	   fluorescent	   residues	   such	   as	   tryptophan	   or	   by	   the	   use	   of	   assays	   in	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which	   a	   fluorescent	   tag	   is	   introduced.	   The	   CBQCA	   assay	   is	   one	   such	   assay	   in	  which	   the	   non-­‐fluorescent	   molecule	   3-­‐(4-­‐Carboxybenzoyl)quinoline-­‐2-­‐carboxaldehyde	  (CBQCA)	  reacts	  with	  primary	  amines	  in	  the	  presence	  of	  cyanide	  to	   form	   a	   highly	   fluorescent	   derivative	   (Figure	   4B).[98]	   After	   acquiring	   a	  calibration	   curve,	   the	  magnitude	   of	   the	   emitted	   fluorescence	   can	   be	   used	   as	   a	  measure	  of	  total	  protein	  content	  of	  a	  sample.	  
	  
Figure	   4.	   A:	   The	   principal	   of	   fluorescence	   illustrated	   with	   a	   Jablonski	   diagram.	   A	   fluorophore	   is	  
excited	  from	  the	  ground	  state	  S0	  to	  the	  excited	  state	  S1	  through	  absorption	  of	  light.	  During	  relaxation	  
back	  to	  the	  ground	  state,	   light	  of	  a	   lower	  energy	  is	  emitted.	  B:	  The	  reaction	  of	   the	  non-­‐fluorescent	  
molecule	   3-­‐(4-­‐Carboxybenzoyl)quinoline-­‐2-­‐carboxaldehyde	   (CBQCA)	   with	   primary	   amines	   in	   the	  
presence	  of	  cyanide	  to	  form	  a	  highly	  fluorescent	  derivative	  used	  to	  quantify	  total	  protein	  content.	  
 Nanoparticle	  tracking	  analysis	  5.2Nanoparticle	  tracking	  analysis	  (NTA)	  is	  a	  nanoparticle	  sizing	  and	  concentration	  determination	   technique	   that	   relies	   on	   visualizing	   particles	   in	   solution	  undergoing	  Brownian	  motion.[99]	  During	  a	  measurement,	  a	  laser	  beam	  is	  passed	  through	  the	  solution	  containing	  the	  nanoparticles,	  which	  are	  visualized	  through	  light	  scattering	  or	  fluorescence	  and	  whose	  diffusion	  is	  recorded	  using	  an	  optical	  microscope	   equipped	   with	   a	   camera	   (Figure	   5).	   Particles	   in	   solution	   undergo	  Brownian	  motion	  in	  three	  dimensions.	  Under	  the	  assumption	  that	  the	  motion	  is	  uniform	  in	  all	  directions,	  the	  captured	  two-­‐dimensional	  motions	  of	  the	  particles	  are	   tracked	   by	   the	   NTA	   software	   in	   order	   to	   determine	   their	   diffusion	  coefficients	  D	  from	  the	  relation:	  	   𝐷 = 𝑧!!!4𝑡 	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where	  z2D2	  is	  the	  mean	  square	  displacement	  in	  two	  dimensions	  during	  the	  time	  t.[100]	  Assuming	  spherical	  particles,	   the	  hydrodynamic	  radius	  r	   is	  given	  by	  the	  two-­‐dimensional	  Stokes-­‐Einstein	  equation:	  𝑟 = 𝑘!𝑇3𝜋𝜂𝐷	  where	  kB	  is	  the	  Boltzmann	  constant,	  T	  is	  the	  temperature	  in	  Kelvin	  and	  η	  is	  the	  solvent	  viscosity.[99]	  The	  hydrodynamic	  radius,	  or	  Stokes	  radius,	  of	  a	  particle	  is	  not	   its	   actual	   physical	   size	   but	   the	   radius	   of	   a	   hard	   sphere	   with	   the	   same	  diffusion	   rate.	   This	   is	   important	   to	   keep	   in	   mind	   when	   working	   with	   non-­‐spherical	  particles.	  	  NTA	   can	   be	   used	   for	   size	   determination	   of	   particles	   with	   diameters	   between	  approximately	   30	   to	   1,000	   nm,	   with	   the	   lower	   limit	   being	   determined	   by	   the	  refractive	  index	  of	  the	  particles.[101]	  	  
	  
Figure	  5.	  Schematic	  of	  a	  nanoparticle	  tracking	  analysis	  setup.	  Particles	  undergoing	  Brownian	  motion	  
in	   solution	   are	   visualized	   through	   scattering	   of	   laser	   light.	   Their	   motions	   are	   tracked	   using	  
specialized	  software	  in	  order	  to	  determine	  their	  diffusion	  constant	  and	  hydrodynamic	  diameter.	  
 Cryogenic	  transmission	  electron	  microscopy	  5.3Transmission	  electron	  microscopy	  (TEM)	  is	  a	  high	  resolution	  imaging	  technique	  in	  which	  the	  image	  contrast	  is	  generated	  by	  the	  scattering	  of	  electrons	  when	  they	  encounter	   structures	   with	   high	   electron	   density	   within	   the	   specimen.	   The	  instrument	   consists	   of	   an	   electron	   source	   emitting	   an	   electron	   beam	   that	   is	  focused	   onto	   the	   specimen	   with	   electromagnetic	   lenses	   and	   a	   detector,	  commonly	   a	   CCD	   camera	   (Figure	   6A).[102,	   103]	   The	   imaging	   is	   by	   necessity	  performed	   in	   vacuum	   to	   avoid	   scattering	   of	   the	   electron	   beam	   by	   air.	   The	  analyzed	   samples	   are	   thin,	   20-­‐90	  nm,	   and	  negative	   staining	   is	   often	   applied	   to	  increase	  the	  contrast.	  Negative	  stains	  generally	  consist	  of	  a	  salt	  of	  a	  heavy	  metal	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with	   a	  high	   atomic	  number	   (42-­‐92)	   that	   forms	  a	   thin	   glassy	   film	  on	   top	  of	   the	  specimen.[102]	   Conventional	   TEM	   on	   hydrated	   systems	   is	   however	   prone	   to	  artifacts	  due	  to	  staining	  and	  shrinking	  due	  to	  drying,	  which	  affects	  the	  perceived	  morphology	  of	  the	  specimen.[102]	  
	  
Figure	  6.	  A:	  Schematic	  representation	  of	  cryogenic	  transmission	  electron	  microscopy;	  scattering	  of	  
electrons	  is	  used	  to	  visualize	  structures	  of	  high	  electron	  density	  in	  a	  cryopreserved	  specimen.	  B:	  In	  a	  
common	   type	   of	   cryopreservation	   the	   specimen,	   in	   solution,	   is	   applied	   to	   a	   lacey	   carbon	   film	  
mounted	  on	  a	  copper	  grid.	  The	  supported	  specimen	  is	  plunged	  into	  a	  cryogen	  leading	  to	  formation	  
of	  vitreous	  ice,	  preserving	  the	  morphology	  of	  fragile	  structures.	  	  To	   overcome	   these	   limitations,	   cryogenic	   TEM	   (Cryo-­‐TEM)	   relies	   on	  cryopreservation	  of	  the	  sample	  prior	  imaging	  to	  minimize	  artifacts.	  The	  sample	  preparation	   is	   aimed	   at	   creating	   vitrified	   specimens	   that	   maintains	   their	  structural	   integrity,	   generally	   through	   plunge	   freezing	   of	   thin	   films	   or	   cryo-­‐sectioning	   of	   bulk	   samples.[102]	   Plunge	   freezing	   is	   a	   fast	   and	   fairly	  straightforward	  method	  in	  which	  a	  small	  amount	  of	  sample	  in	  liquid	  suspension	  form	  is	  added	  to	  a	  supporting	  substrate,	  often	  a	  lacey	  carbon	  film	  supported	  by	  a	  copper	   grid.	   The	   sample	   is	   blotted	   with	   filter	   paper	   so	   that	   only	   a	   thin	   film	  remains	   on	   the	   substrate	   and	   is	   then	   plunged	   into	   a	   cryogen	   with	   high	   heat	  capacity,	  such	  as	  liquid	  ethane	  at	  around	  -­‐183	  °C.	  Due	  to	  the	  very	  rapid	  freezing	  rate,	   the	   liquid	   suspension	   vitrifies	   instead	   of	   forming	   crystalline	   ice,	   thus	  keeping	   the	   structures	   within	   intact	   (Figure	   6B).	   The	   vitrified	   samples	   are	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transferred	   to	   the	   electron	  microscope’s	   cryoholder	   under	   liquid	   nitrogen	   and	  are	  viewed	  at	  around	  -­‐173	  °C	  under	  vacuum.[102]	  	  Due	  to	  the	  thinness	  of	  the	  film	  formed	  through	  this	  preparation	  method,	  it	  may	  be	  difficult	  to	  visualize	  larger	  structures.	  Furthermore,	  the	  elements	  comprising	  biomacromolecules	   and	   polymers,	   such	   as	   proteins	   and	   PEG,	   generally	   do	   not	  scatter	   enough	   to	   provide	   sufficient	   contrast	   to	   be	   readily	   visible	   with	   Cryo-­‐TEM.[102]	   Cryo-­‐TEM	   of	   protein-­‐	   and/or	   polymer-­‐conjugated	   lipid	   particles	  therefore	   gives	   information	   about	   the	   size	   and	   morphology	   of	   the	   lipid	  structures	  only,	  unless	  additional	   labeling	   is	  performed.	   It	   is	   important	   to	  note	  that	  since	  Cryo-­‐TEM	  gives	  information	  about	  the	  physical	  size	  of	  particles,	  it	  can	  be	  misleading	  to	  directly	  compare	  sizes	  measured	  from	  Cryo-­‐TEM	  images	  to	  data	  obtained	   with	   other	   sizing	   techniques	   that	   measures	   the	   hydrodynamic	   size,	  such	  as	  NTA	  or	  dynamic	  light	  scattering	  (DLS).	  	  
 Laser	  Doppler	  electrophoresis	  5.4The	  charge	  of	  particles	  is	  commonly	  assessed	  by	  measuring	  their	  electrophoretic	  mobility,	  i.e.	  their	  velocity	  in	  an	  electric	  field.[26]	  This	  measure	  is	  independent	  of	  shape	  and	  size	  and	  can	  be	  assessed	  using	   laser	  Doppler	  electrophoresis	   (LDE).	  An	  LDE	  instrument	  generally	  consists	  of	  a	  laser	  providing	  collimated	  light	  that	  is	  split	   into	   two	   beams:	   the	   scattering	   beam	   and	   the	   reference	   beam	   (Figure	  7A).[104]	  The	  scattering	  beam	  enters	  the	  scattering	  volume,	  an	  electrophoretic	  cell	   that	   contains	   the	   specimen,	   a	   suspension	   of	   particles,	   which	   scatters	   the	  incoming	   light.	   The	   movement	   of	   the	   particles	   undergoing	   electrophoresis	  causes	  a	  shift	  in	  the	  frequency	  Δf	  of	  the	  scattered	  light	  compared	  to	  the	  reference	  beam	  due	  to	  the	  Doppler	  effect	  according	  to:	  ∆𝑓 = 2𝑣 ∙ sin  (𝜃/2)𝜆 	  where	   v	   is	   the	   particle	   velocity,	   λ	   is	   the	  wavelength	   of	   light	   used	   and	  Θ	   is	   the	  scattering	   angle.[104]	   The	   light	   scattered	   at	   the	   angle	   Θ	   is	   combined	  with	   the	  reference	  beam	  before	  arriving	  at	  the	  detector.	  Analysis	  of	  the	  Doppler	  shift	  can	  be	   made	   using	   phase	   analysis	   light	   scattering	   in	   order	   to	   deduce	   the	  electrophoretic	  mobility	  of	  the	  particles.	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Figure	  7.	  A:	  Schematic	  representation	  of	  a	  Laser	  Doppler	  electrophoresis	   instrument;	   laser	   light	   is	  
split	   into	  a	   reference	  beam	  and	  a	   scattering	  beam,	  which	   is	   scattered	  by	   the	  particles	  undergoing	  
microelectrophoresis.	   The	   frequency	   shift	   between	   the	   reference	   beam	   and	   the	   light	   scattered	   at	  
angle	  θ,	  due	  to	  the	  Doppler	  shift	  is	  used	  to	  deduce	  the	  electrophoretic	  mobility	  of	  the	  particles	  which	  
is	   used	   to	   determine	   the	   zeta	   potential.	   B:	   The	   zeta	   potential	   is	   the	   electric	   potential,	   not	   at	   the	  
particle	  surface,	  but	  at	  the	  slipping	  plane	  at	  the	  edge	  of	  the	  diffuse	  electric	  double	  layer	  comprising	  
ions	  loosely	  associated	  with	  the	  particle.	  The	  oscillating	  electric	  field	  applied	  during	  LDE	  causes	  the	  particles	  to	  move	  at	  a	  velocity	  that	  is	  proportional,	  not	  to	  the	  charge	  directly	  at	  the	  particle	  surface,	  but	  rather	   to	   the	   zeta	   potential,	  which	   is	   the	   electrostatic	   potential	   at	   the	   slipping	  plane	   at	   the	   edge	   of	   the	   diffuse	   electric	   double-­‐layer	   surrounding	   charged	  particles	   (Figure	   7B).	   The	   double-­‐layer	   consists	   of	   differently	   charged	   ions	  distributed	  in	  the	  near	  vicinity	  of	  the	  particle	  surface,	  thus	  shielding	  the	  surface	  charge.	  The	  thickness	  of	  the	  double	  layer	  is	  also	  known	  as	  the	  Debye	  length	  and	  is	  defined	  as	  the	  distance	  from	  the	  surface	  where	  the	  potential	  has	  fallen	  to	  1/e	  of	   its	   value	   at	   the	   surface.[26]	  The	   zeta	  potential	   ζ	   can	  be	   calculated	  using	   the	  Henry	  equation:	   𝜍 = 3µμ𝜂2𝜀!𝐷 𝑓(𝜅𝑎)	  where	  μ	  is	  the	  electrophoretic	  mobility,	  ε0	  is	  the	  permittivity	  of	  vacuum,	  η	  and	  D	  are,	   respectively,	   the	   viscosity	   and	   the	   dielectric	   constant	   of	   the	   dispersion	  medium	   and	   a	   is	   the	   particle	   radius.[105]	   f(κa)	   is	   Henry’s	   function	   which	  depends	  on	   the	  Debye	   length	  κ-­‐1.	  The	  magnitude	  of	  both	   the	  Debye	   length	  and	  the	  zeta	  potential	  do	  not	  only	  depend	  on	  the	  particle	  charge,	  but	  also	  on	  the	  ionic	  strength	  and	  pH	  of	  the	  medium	  in	  which	  the	  particles	  are	  dispersed.[26]	  In	  cases	  where	   the	   particle	   radius	   is	   much	   larger	   than	   the	   Debye	   length	   (κa>>1),	   the	  Henry	   equation	   can	   be	   simplified	   using	   the	   Smoluchowski	   approximation	   of	  f(κa)=1.5,	  giving:	   𝜍 = µμ𝜂𝜀!𝐷	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[105,	   106]	  At	   physiological	   ionic	   strength,	   the	  Debye	   length	   is	   on	   the	   order	   of	  nanometers,	  so	  this	  approximation	  is	  thus	  often	  suitable.[26]	  	  
 Light	  microscopy	  5.5Methods	   capable	   of	   identifying	   and	   quantifying	   cellular	   responses	   are	   useful	  when	   assessing	   how	   particle	   properties	   affect	   key	   events	   in	   the	   immune	  response.	  In	  the	  context	  of	  vaccination	  key	  events	  include	  antigen	  uptake	  by	  an	  APC.	   Uptake	   processes	   can	   be	   characterized	   and	   quantified	   using	   microscopy	  and	   current	   high-­‐resolution	   imaging	   methods	   provide	   opportunities	   to	   do	   so	  with	  precision.	  In	  particular,	  live-­‐cell	  imaging	  allows	  us	  to	  observe	  the	  dynamics	  of	  such	  processes	   in	  real-­‐time.	   In	   this	  chapter,	  a	  brief	  overview	  of	   the	  basics	  of	  optical	   microscopy,	   some	   specialized	   microscopy	   techniques	   and	   examples	   of	  how	  they	  have	  been	  used	  to	  study	  cellular	  uptake	  of	  different	  types	  of	  particles	  in	  sizes	  ranging	  from	  tens	  to	  a	  few	  hundred	  nm	  will	  be	  given.	  	  Convex	   lenses	   have	   been	   used	   for	   more	   than	   five	   hundred	   years	   to	   magnify	  objects	   beyond	   the	   human	   eye’s	   ability	   to	   observe	   and	   the	   invention	   of	   the	  microscope	   took	  place	   in	   the	  17th	  century.[107]	  Thanks	   to	   these	  advances,	  we	  have	  been	  able	  to	  visualize	  and	  understand	  microorganisms,	  our	  own	  cells	  and	  eventually	  also	  their	  constituents.	  	  	  There	  are	  many	  microscopy	  subtypes	  and	  setups	  but	  the	  basic	  construction	  of	  an	  optical	  microscope	  is	  mostly	  the	  same	  in	  all	  cases.	  In	  essence,	   light	  from	  a	  light	  source	   such	   as	   a	   lamp,	   LED	   or	   laser	   passes	   through	   a	   condenser	   and	   then	  interacts	   with	   a	   specimen.[107]	   The	   light	   is	   collected	   by	   the	   objective,	   which	  contains	  one	  or	  several	  lenses	  and	  that	  helps	  focus	  the	  image	  of	  the	  specimen	  at	  the	   optical	   plane	   of	   an	   eyepiece	   or	   a	   camera.[107]	   In	   the	   simplest	   form	   of	  microscopy,	  brightfield,	  the	  light	  is	  simply	  transmitted	  through	  the	  specimen;	  all	  the	  light	  is	  collected	  and	  the	  contrast	  is	  given	  by	  the	  attenuation	  of	  the	  light	  due	  to	  the	  sample.	  However,	  many	  specimens	  have	   low	  contrast,	  making	  structures	  difficult	  to	  separate	  from	  the	  background.	  Therefore,	  there	  are	  variants	  of	  optical	  microscopy	  aimed	  at	   enhancing	   the	   contrast,	   such	  as	  darkfield,	  phase	   contrast,	  polarization	   microscopy	   and	   differential	   interference	   contrast	   (DIC).[108-­‐111]	  In	   addition	   to	   the	   contrast,	   the	   resolution	   is	   a	   critical	   parameter	   for	   how	  well	  small	   objects	   are	   visualized	   using	   light	   microscopy.	   The	   resolution	   limit	   is	   a	  constraint	   that	   the	   wavelike	   properties	   of	   light	   place	   on	   conventional	   light	  microscopy.	  When	  light	  from	  a	  point	  source	  passes	  through	  a	  circular	  aperture,	  such	  as	  a	   lens,	   it	   is	  diffracted	  and	  will	  appear	  as	  a	  bright	  spot	  surrounded	  by	  a	  series	   of	   concentric	   circles	   (an	   Airy	   disk	   and	   Airy	   pattern).[112]	   When	   two	  objects	   come	   close	   together,	   their	   Airy	   patterns	   overlap	   and	   they	   cannot	   be	  visually	   separated.	   Ernst	   Abbe	   formulated	   the	   dependency	   of	   the	   resolution	  limit,	  d,	  on	  the	  wavelength	  of	  the	  light,	  λ,	  and	  the	  objective	  used	  for	  imaging:	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d = λ2n  sinθ = λ2NA	  where	  n	  is	  the	  refractive	  index	  of	  the	  medium,	  θ	  is	  the	  half	  angle	  subtended	  by	  the	  objective	  and	  NA	  is	  the	  numerical	  aperture	  of	  the	  objective.[113]	  For	  modern	  instruments,	   this	   means	   approximately	   half	   the	   wavelength	   of	   the	   light,	   in	  practice.	  	  	  An	   important	  component	  of	  many	  modern	  microscopy	   techniques	   is	   the	  use	  of	  fluorescent	   labels,	   such	   as	   antibodies	   conjugated	   to	   fluorophores	   (see	   section	  5.1)	   or	   proteins	   which	   are	   expressed	   with	   the	   tag	   directly	   attached.	   This	   has	  been	   crucial	   not	   only	   to	   detect	   objects	   smaller	   than	   a	   couple	   hundred	  nanometers	   but	   also	   to	   visualize	   cellular	   structures	   and	   observe	   dynamic	  processes,	   such	   as	   uptake.	   Fluorescence	   has	   been	   instrumental	   in	   the	  development	  of	   the	   imaging	   field,	  both	  as	  a	  means	   to	   improve	   the	  contrast	  but	  additionally	  in	  allowing	  us	  to	  move	  beyond	  Abbe’s	  limit	  using	  techniques	  such	  as	  confocal	  laser	  scanning	  microscopy	  and	  super-­‐resolution	  imaging.	  
5.5.1 Widefield	  Fluorescence	  Microscopy	  The	   simplest	   type	   of	   fluorescence	   microscopy	   is	   widefield	   fluorescence	  microscopy,	   or	   epifluorescence	   microscopy.	   In	   this	   technique,	   multichromatic	  light	   is	   sent	   through	   an	   optical	   excitation	   filter	   that	   allows	   only	   light	   of	  wavelengths	  suitable	  for	  excitation	  of	  a	  particular	  fluorophore	  to	  pass;	  the	  light	  meets	  the	  main	  beam	  splitter,	  a	  component	  that	  selectively	  reflects	  or	  transmits	  light	  of	  different	  wavelengths.	  The	  beam	  splitter,	  or	  dichromatic	  mirror,	  reflects	  the	   short	   wavelength	   excitation	   light	   through	   the	   objective	   and	   onto	   the	  specimen.	   The	   light	   emitted	   by	   fluorophores	   in	   the	   sample	   is	   collected	   by	   the	  objective	  and	  meets	  the	  main	  beam	  splitter,	  which	  transmits	  this	  light	  that	  then	  passes	  through	  an	  emission	  filter	  that	  allows	  light	  of	  only	  certain	  wavelengths	  to	  pass	   to	   the	   eyepiece	   or	   camera	   (Figure	   8).[114]	   The	   excitation	   and	   emission	  filters	   together	  with	   the	  dichromatic	  mirror	  are	  generally	  mounted	   into	  a	   filter	  cube.	   It	   is	   common	   to	   have	  multiple	   filter	   cubes	   suitable	   for	   imaging	   different	  fluorophores.	   One	   can	   then	   switch	   from	   one	   to	   the	   other	   and	   image	   different	  labeled	  structures	  in	  sequence.[115]	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Figure	  8.	  General	  setup	  of	  a	  widefield	  fluorescence	  microscope.	  	  Widefield	  fluorescence	  microscopy	  has	  been	  applied	  to	  study	  cellular	  uptake	  of	  different	  particles	  of	  interest.	  Van	  der	  Schaar	  et	  al.	  used	  widefield	  microscopy	  to	  study	   cellular	   uptake	   of	   DiD-­‐labelled	   Dengue	   virus.[116]	   They	   elucidated	   both	  the	  clathrin-­‐mediated	  internalization	  process	  and	  the	  endocytic	  trafficking	  of	  the	  virus	   through	   fluorescent	   labeling	   of	   endocytic	   machinery	   components.[116]	  Using	  HIV-­‐1	  virus-­‐like	  particles	  (VLPs),	  Endreß	  et	  al.	  showed	  two	  types	  of	  HIV-­‐cell	  interactions:	  either	  the	  VLPs	  became	  immobilized	  upon	  contact	  or	  there	  was	  a	   very	   short-­‐lived	   dynamic	   interaction	   (in	   the	   range	   of	   20-­‐50	  ms)	   followed	  by	  dissociation.[117]	  de	  Bruin	  et	   al.	   used	  epidermal	  growth	   factor	   (EGF)	   to	  direct	  delivery	   of	   polyethylenimine	   polyplexes	   to	   cancer	   cells	   that	   overexpress	   EGF	  receptor	   (EGFR).	   Widefield	   microscopy	   revealed	   faster	   and	   more	   efficient	  internalization	   of	   EGFR-­‐targeted	   compared	   to	   untargeted	   polyplexes.[118]	  Furthermore,	   Tian	   et	   al.	   studied	   cellular	   uptake	   and	   processing	   of	  exosomes.[119]	   Single	   particle	   tracking	   was	   used	   to	   study	   the	   movement	   of	  exosomes	   in	  medium,	  on	   the	   cell	   surface	   and	   intracellularly	   in	   endosomes	  and	  lysosomes,	   identifying	   distinct	   movement	   patterns	   distinguishing	   membrane-­‐bound	   from	   freely	   diffusing	   exosomes.	   Trypan	   blue	   was	   used	   to	   distinguish	  between	   intra-­‐	  and	  extracellular	  DiI-­‐labelled	  exosomes.	  Octadecyl	  rhodamine	  B	  chloride	   (R18)-­‐labelled	   exosomes	   were	   used	   to	   discern	   that	   exosomes	   were	  taken	  up	  through	  endocytosis	  and	  not	  fusion	  with	  the	  cell	  membrane.[119]	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  A	  drawback	  of	  widefield	   fluorescence	  microscopy	   is	   that	   since	  all	  emitted	   light	  within	  a	  wavelength	  range	  is	  collected,	  there	  is	  usually	  a	  high	  background	  from	  out-­‐of-­‐focus	   fluorophores.	   Total	   internal	   reflection	   fluorescence	   (TIRF)	  microscopy	   is	   one	   technique	   that	   has	   been	   developed	   in	   order	   to	   address	   this	  issue.	  
5.5.2 Total	  Internal	  Reflection	  Fluorescence	  Microscopy	  TIRF	   microscopy	   is	   a	   surface	   sensitive	   technique	   that	   relies	   on	   selectively	  exciting	  fluorophores	  using	  an	  illumination	  depth	  restricted	  to	  the	  area	  closest	  to	  an	   interface	   between	   two	  materials	   of	   different	   refractive	   indices,	   n1	   and,	   n2.	  The	  fluorophores	  that	  are	  outside	  of	  the	  illuminated	  area	  remain	  unexcited	  and	  do	  not	  contribute	  to	  the	  background	  fluorescence.	  The	  materials	  of	  the	  interface	  are	   generally	   a	   sample,	  with	   low	   refractive	   index,	   e.g.	  water,	   on	   top	   of	   a	   glass	  coverslip,	  with	  high	  refractive	  index,	  as	  seen	  in	  Figure	  9.[120]	  	  	  
	  
Figure	  9.	   Schematic	   of	  TIRF	  microscopy.	  When	   incident	   light	   of	   angle	  θ1,	   greater	   than	   the	   critical	  
angle	  θc,	  encounters	  an	  interface	  between	  a	  medium	  with	  high	  refractive	  index	  (n1,	  coverslip)	  and	  a	  
mediim	  with	  low	  refractive	  index	  (n2,	  sample),	  the	  light	  is	  totally	  internally	  reflected.	  This	  leads	  to	  
the	  formation	  of	  an	  evancescent	  field	  that	  extends	  a	  small	  distance	  into	  the	  sample.	  Thus,	  only	  the	  
fluorophores	  whithin	  this	  field	  emit	  fluorescence	  while	  fluorophores	  that	  are	  further	  away	  from	  the	  
interface	  remain	  unexcited.	  How	   a	   light	   beam	   is	   refracted	   when	   passing	   through	   such	   an	   interface	   is	  described	  by	  Snell’s	  law:	   n! sin θ! = n! sin θ!	  where	  θ1	  is	  the	  angle	  of	  incident	  light	  and	  θ2	  is	  the	  angle	  of	  refracted	  light.	  	  If	  the	  second	  material	  has	  a	  lower	  refractive	  index	  than	  the	  first	  (n1	  >n2)	  and	  the	  angle	  of	   incidence	   is	  equal	   to	  what	   is	   termed	   the	  critical	  angle,	  θc,	   the	  refracted	   light	  will	  travel	  along	  the	  interface	  of	  the	  two	  materials.	  The	  critical	  angle	  is	  given	  by:	  θ! = sin!! n!n!	  If	  the	  angle	  of	  incidence	  is	  larger	  than	  the	  critical	  angle	  (θ1>θc),	  the	  light	  is	  totally	  internally	   reflected	   at	   the	   interface,	   giving	   rise	   to	   an	   evanescent	   field	   that	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extends	   a	   small	   distance	   into	   the	   second	   material.[120]	   The	   light	   intensity,	   I,	  decays	  exponentially	  with	  the	  distance	  from	  the	  interface,	  z,	  according	  to:	  I z = I!e!! !	  where	  I0	  is	  the	  intensity	  at	  the	  interface	  and	  d	  is	  the	  characteristic	  decay	  depth,	  defined	  as:	   d = λ4πn! sin!θsin!θ! − 1 !! !	  where	   λ	   is	   the	   wavelength	   of	   the	   incident	   light.[121]	   The	   surface-­‐confined	  illumination	   eliminates	   background	   fluorescence,	   making	   TIRF	   microscopy	   a	  technique	  with	  high	  signal-­‐to-­‐noise	  ratio.	  	  TIRF	  microscopy	  has	  been	  used	  to	  study	  cellular	  uptake	  for	  example	  by	  Schmidt	  et	  al.,	  who	  studied	  pH-­‐triggered	   fusion	  of	  vaccinia	  virions	   to	  HeLa	  cells	  using	  a	  microfluidic	   cell	   trap.[122]	   The	   viruses	   were	   labelled	   with	   a	   self-­‐quenching	  concentration	  of	  R18	  and	  the	  virus	  cores	  were	  GFP-­‐tagged.	  A	  reduction	  of	  the	  pH	  was	  used	  to	  induce	  fusion,	  which	  caused	  dequenching	  of	  the	  R18	  simultaneous	  to	  reduction	   of	   the	  GFP	   signal	   due	   to	   internalization	   of	   the	   virus	   core.[122]	  TIRF	  has	  also	  been	  used	  to	  visualize	  quantum	  dot	  diffusion	  on	  the	  surfaces	  of	  immune	  cells,	   with	   single	   particle	   tracking	   used	   to	   determine	   diffusion	   constants,	  followed	  by	  uptake	  quantified	  by	  measuring	  the	  overall	  decrease	  in	  fluorescence	  as	  the	  quantum	  dots	  disappeared	  from	  the	  field	  of	  view	  when	  taken	  up.[123]	  It	  was	  shown	  that	  the	  size	  and	  shape	  of	  the	  quantum	  dots	  influence	  both	  their	  final	  intracellular	   fate	   and	   their	   behavior	   on	   the	   cell	   membrane;	   more	   specifically,	  quantum	   dots	   with	   a	   high	   aspect	   ratio	   exhibited	   slower	   movement.[123]	  Furthermore,	  TIRF	  has	  been	  used	  to	  show	  the	  dynamics	  of	  cholesterol-­‐modified	  Cy3-­‐labelled	  siRNA	  internalization.[124]	  
 Flow	  cytometry	  5.6An	   important	  step	  of	   the	   immune	  response	   is	   the	  antigen	  presentation	  by	  DCs,	  which	  is	  a	  crucial	  step	  for	  activation	  of	  T	  cells.	  The	  amount	  of	  antigen	  presented	  on	   the	  DC	   surface	   in	   response	   to	   changes	   in	   the	  physicochemical	  properties	  of	  vaccine	  vectors	  can	  be	  assessed	  using	  flow	  cytometry.	  Indeed,	  flow	  cytometry	  is	  often	  used	  for	  characterization	  and	  quantification	  of	  cells	  and	  cell	  constituents.	  It	  is	  a	  popular	  technique	  in	  different	  fields	  of	  research	  and	  has	  a	  set	  of	  uses	  ranging	  from,	   for	   example,	   determination	   of	   cell	   viability	   to	   quantification	   of	  phagocytosis.[125,	  126]	  In	  recent	  years,	  flow	  cytometry	  has,	  in	  addition	  to	  being	  an	  invaluable	  research	  tool,	  become	  an	  important	  diagnostic	  and	  prognostic	  tool	  in	   the	   clinical	   treatment	   of	   cancer	   and	   immunological	   diseases.[127]	  Furthermore,	   the	   use	   of	   flow	   cytometry	   has	   stretched	   beyond	   the	   analysis	   of	  cells	   to	   also	   include	   biologically	   relevant	   micro-­‐	   and	   nanoparticles,	   such	   as	  exosomes.[128]	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The	  large	  variety	  of	  applications	  and	  their	  increasing	  complexity	  aside,	  the	  flow	  cytometry	   technique	   relies,	   in	   essence,	   on	   three	   basic	   building	   blocks:	   1)	   the	  arranging	  of	  the	  cells	  into	  a	  single	  file	  through	  a	  flow	  cell,	  2)	  the	  optical	  system	  comprising	   one	   or	   several	   lasers	   generating	   the	   illumination	   of	   the	   sensing	  volume	  through	  which	  the	  cells	  pass,	  as	  well	  as	  a	  set	  of	  lenses	  and	  filters	  to	  focus	  and	   direct	   the	   light	  which	   is	   scattered	   and/or	   emitted	   by	   the	   cells,	   and	   3)	   the	  electronics	  used	  to	  convert	  this	  light	  to	  an	  electronic	  signal.	  Due	  to	  the	  different	  components	   comprising	   a	   flow	   cytometer,	   one	   might	   say	   that	   there	   is	   not	   a	  singular	  origin	  of	   the	  technique,	  but	  rather	  several	  advancing	  paths	  converging	  into	   the	  development	  of	  cell	  microfluorometry	  by	  van	  Dilla	  et	  al.	   in	  1965.[129]	  This	   chapter	   will	   give	   a	   brief	   overview	   of	   the	   theory	   behind	   flow	   cytometry,	  describing	  a	  typical	  instrument	  and	  the	  physical	  phenomena	  it	  employs.	  	  
5.6.1 Principles	  and	  instrument	  design	  As	   previously	   touched	   upon,	   a	   flow	   cytometer	   can	   be	   said	   to	   consist	   of	   three	  main	   components:	   a	   microfluidic	   system,	   an	   optical	   system	   and	   an	   electronic	  system	  that	  function	  in	  a	  synchronized	  manner	  (Figure	  10).[130]	  In	  this	  section,	  each	  of	  these	  systems	  is	  presented	  in	  some	  detail.	  
5.6.1.1 Microfluidics	  The	  role	  of	  the	  microfluidic	  system	  is	  to	  ensure	  that	  the	  cells	  pass	  in	  a	  controlled	  manner	  one	  by	  one	   through	   the	   sensing	  volume,	  or	   interrogation	  point	   as	   it	   is	  sometimes	   referred	   to.	   This	   is	   crucial	   to	   maintain	   uniform	   and	   reproducible	  illumination	  conditions.	  The	  arrangement	  of	  cells	   into	  “a	  single	  file”	   is	  achieved	  through	  hydrodynamic	  focusing	  by	  use	  of	  a	  sheath	  flow.	  A	  pressurized	  stream	  of	  sheath	  fluid	  is	  maintained	  into	  which	  the	  sample	  is	  injected	  at	  a	  higher	  pressure,	  causing	   a	   difference	   in	   flow	   speeds	   between	   the	   two	   fluids	   that	  maintains	   the	  cells	   in	   the	   central	   stream,	   the	   “core”.	   A	   strategic	   narrowing	   of	   the	   flow	   cell	  causes	   a	   simultaneous	   increase	   of	   the	   flow	   speed	   and	   a	   decrease	   of	   the	   core	  cross-­‐section	  to	  the	  point	  where	  cells	  generally	  pass	  through	  the	  sensing	  volume	  one	   by	   one.[131]	   Generally	   speaking,	   it	   is	   crucial	   to	  maintain	   laminar	   flow	   by	  avoiding	  e.g.	  too	  acute	  narrowing	  of	  the	  flow	  cell	  and	  sharp	  edges	  in	  the	  design	  as	  well	  as	  blockages	  and	  air	  bubbles	  during	  operation.	  The	  nature	  of	  the	  flow	  in	  a	  tube	  is	  determined	  by	  four	  parameters,	  whose	  relationship	  is	  often	  expressed	  by	  the	  dimensionless	  Reynolds	  number,	  Re:	  	  𝑅𝑒 = 𝑣𝑑𝜌𝜇 	  where	  v	  [m/s]	  is	  the	  average	  velocity	  throughout	  the	  cross-­‐section	  of	  the	  tube,	  d	  [m]	   is	   the	   tube	   diameter,	   ρ	   [kg/m3]	   and	   µ	   [kg/sm]	   is	   the	   fluid	   density	   and	  viscosity,	  respectively.	  At	  Re	  greater	  than	  2,300	  the	  laminar	  flow	  starts	  to	  break	  down	  in	  favour	  of	  turbulence.[132]	  The	  sensing	  volume	  is	  generally	  located	  in	  an	  area	  with	  	  “slug	  flow”,	  characterized	  by	  constant	  flow	  speed	  across	  the	  diameter	  of	   the	   core,	   a	   result	   of	   the	   aforementioned	   narrowing	   of	   the	   flow	   cell.	   This	   is	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advantageous	  as	  it	  minimizes	  the	  velocity	  differences	  between	  cells	  at	  different	  distances	  from	  the	  centre	  of	  the	  core	  compared	  to	  the	  parabolic	  flow	  profile	  of	  a	  laminar	  flow	  that	  arises	  from	  the	  no-­‐slip	  boundary	  condition.[131]	  	  
5.6.1.2 Optics	  When	  cells	  pass	  through	  the	  sensing	  volume,	  i.e.	  the	  laser	  beam,	  the	  light	  that	  is	  scattered,	  and	  emitted	  in	  the	  case	  of	  fluorescently	  labeled	  cells,	  gives	  information	  about	   their	  properties.	  Physically	  speaking,	  scattered	   light	  consists	  of	   light	   that	  has	   been	   diffracted,	   reflected,	   refracted,	   anomalously	   diffracted	   and	   Rayleigh	  scattered.[132]	  Maxwell’s	  equations	  can	  be	  solved	  to	  describe	  the	  propagation	  of	  light	  after	  it	  has	  been	  scattered	  by	  an	  object.	  In	  the	  case	  of	  a	  cell,	  there	  are	  many	  intracellular	   objects	   with	   varying	   properties,	   and	   the	   morphological	   and	  biochemical	  complexity	  of	  a	  cell	  thus	  make	  the	  mathematical	  description	  of	  this	  process	  challenging	  even	  though	  it	  has	  been	  attempted.[133-­‐137]	  Such	  modeling	  is	  however	  not	  standard	  in	  flow	  cytometry,	  where	  the	  light	  scattering	  properties	  of	  cells	  are	  measured	  and	  related	  to	  two	  main	  properties.	  Light	  that	  is	  deflected	  around	   the	   edges	   of	   the	   cells,	   parallel	   to	   the	   direction	   of	   the	   laser	   beam,	   is	  termed	   forward	  scatter	   (FSC)	  and	  gives	   information	  about	   the	  size	  of	   the	  cells.	  Light	   that	   is	   scattered	  perpendicularly	   to	   the	   laser	  beam	   is	   termed	  side	  scatter	  (SSC).	   Side-­‐scattered	   light	   is	   primarily	   scattered	   from	   intracellular	   structures,	  therefore	  giving	  information	  about	  the	  internal	  complexity.[126]	  The	  intensity	  of	  the	  SSC	  is	  proportional	  to	  what	  is	  often	  termed	  cell	  granularity.	  	  	  In	  addition	  to	  the	  information	  from	  the	  scattered	  light,	  which	  is	  obtained	  label-­‐free,	  features	  of	  interest	  can	  be	  tagged	  with	  fluorescent	  labels	  (see	  section	  5.1).	  Fluorescent	  probes	  are	  utilized	  in	  order	  to	  detect	  and	  quantify	  the	  amount	  of	  for	  example	   nucleic	   acids,	   proteins	   or	   to	   assess	   cell	   viability.[126]	   Since	   different	  fluorophores	  have	  different	  emission	  and	  excitation	  spectra,	  a	  cell	  can	  be	  stained	  with	   several	   probes	   with	   different	   fluorophores	   (fluorochromes).	   The	   most	  common	   fluorophores	   used	   for	   flow	   cytometry	   include	   fluorescein	  isothiocyanate	   (excitation/emission	   495/520	   nm),	   phycoerythrin	  (excitation/emission	   565/578	   nm)	   and	   allophycocyanin	   (excitation/emission	  650/660	   nm).[126]	   Once	   excited	   by	   lasers	   with	   light	   of	   suitable	   wavelengths,	  monochromatic	  mirrors	  and	  optical	   filters	  are	  used	  to	  guide	  emitted	   light	   from	  different	  fluorochromes	  in	  different	  “channels”	  to	  different	  detectors	  (see	  section	  5.5.1).[131]	  
5.6.1.3 Electronics	  The	  electronic	  system	   in	  a	   flow	  cytometer	  consists	  of	  a	  series	  of	  detectors	   that	  convert	   the	   scattered	   and	   emitted	   light	   into	   electrical	   currents	   that	   can	   be	  recorded	   and	   visualized.	   There	   are	   generally	   two	   types	   of	   detectors	   used:	  photodiodes	   and	   photomultiplier	   tubes.	   Photodiodes	   are	   typically	   used	   for	   the	  FSC,	  which	  has	  a	  high	  intensity,	  while	  photomultiplier	  tubes	  are	  used	  to	  amplify	  
	  	   38	  
and	   detect	   SSC	   and	   emitted	   light.[138]	   In	   both	   cases,	   the	   output	   signal	   is	  proportional	  to	  the	  incoming	  number	  of	  photons.[126]	  	  
	  
Figure	  10.	  A:	  A	  schematic	  representation	  of	  a	  flow	  cytometer.	  The	  microfluidic	  system	  arranges	  the	  
cells	  into	  a	  single	  file	  through	  the	  beam	  of	  one	  of	  several	  differently	  colored	  lasers,	  i.e.	  the	  sensing	  
volume,	   B.	   The	   light	   that	   is	   scattered	   parallel	   to	   the	   laser	   beam,	   termed	   forward	   scatter	   (FSC),	  
provides	   information	   about	   the	   size	   of	   the	   cells	   and	   the	   light	   that	   is	   scattered	   perpendicularly,	  
termed	  side	  scatter	  (SSC),	  gives	  information	  about	  the	  internal	  complexity	  of	  the	  cells.	  	  Dichromatic	  
mirrors	   and	   optical	   filters	   are	   used	   to	   guide	   the	   SSC	   and	   light	   emitted	   from	   fluorescent	   labels	   to	  
different	  photomultiplier	  tubes	  (PMTs).	  
5.6.2 Data	  analysis	  In	   flow	   cytometry	   many	   parameters	   are	   usually	   measured	   on	   numerous	  individual	   cells,	   which	   means	   that	   a	   large	   and	   important	   part	   of	   the	   method	  comprises	  the	  processing	  of	  the	  data.	  Common	  ways	  to	  display	  the	  data	  include	  dot	  plots,	  which	  visualize	  the	  magnitude	  of	  two	  parameters	  at	  the	  same	  time,	  and	  histograms,	  which	  visualize	  the	  number	  of	  cells	  and	  to	  which	  degree	  they	  are,	  for	  example,	  expressing	  a	  marker	  of	  interest.	  	  
5.6.2.1 Spectral	  compensation	  Spectral	   (or	   colour)	   compensation	   is	   a	   standard	   procedure	   used	  when	   several	  fluorochromes	  are	  used	  in	  one	  measurement.	  Overlap	  of	  the	  emission	  spectra	  of	  the	  fluorophores	  means	  that	  light	  from	  several	  fluorochromes	  can	  pass	  through	  the	  emission	  filters	  and	  be	  detected	  in	  the	  same	  channel.	  Spectral	  compensation	  is	   thus	   needed	   to	   adjust	   for	   the	   light	   each	   fluorochrome	   contributes	   with	   in	  channels	  other	  than	  its	  own,	  and	  is	  done	  by	  measuring	  each	  fluorochrome	  alone	  and	  calculating	  how	  much	  of	  the	  total	  light	  each	  contribute	  with	  to	  the	  different	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channels.[126]	  This	   information	   is	   then	  used	   to	   compensate	   for	  any	  overlap	   in	  the	  subsequent	  measurement.[139]	  
5.6.2.2 Gating	  Gating	   is	   a	   process	   commonly	   used	   to	   eliminate	   results	   from	   debris	   and	   dead	  cells	  and	  to	  subsequently	  enumerate	  cells	  with	  certain	  properties.[126]	  Cells	  are	  visualized	   in	   a	   two-­‐dimensional	   scatter	   plot	   in	   which	   the	   user	   defines	   one	   or	  several	  regions,	  restricting	  further	  analysis	  to	  certain	  subsets	  of	  cells.	  By	  in	  this	  manner	   iteratively	   visualizing	   and	   zooming	   in	   on	   cells	   with	   a	   certain	   set	   of	  markers,	   identification	   and	   quantification	   of	   cell	   subpopulations	   is	  performed.[140]	  
5.6.2.3 Computational	  flow	  cytometry	  As	   progressively	   large	   and	   complex	   datasets	   are	   collected,	   the	   challenge	   in	  manually	  analyzing	  the	  data	   is	   increasing.	   It	   is	   impossible	  to	   fully	  visualize	  and	  manually	  see	  relationships	  between	  all	  parameters	  that	  modern	  flow	  cytometers	  are	  capable	  to	  measure	  at	  once.	  Therefore,	  dimensionality	  reduction	  techniques	  such	   as	   principal	   component	   analysis	   (PCA)	   and	   t-­‐stochastic	   neighbor	  embedding	   (t-­‐SNE)	   aimed	   at	   projecting	   high-­‐dimensional	   data	   into	   two-­‐dimensional	   representations	   provides	   useful	   overviews.[140]	   Automated	  clustering	  methods	   are	   useful	   to	   find	   and	   group	   similar	   objects	   together.	   Cells	  with	  similar	  profiles	  are	  assigned	   to	  clusters,	  which	  can	   then	  be	   interpreted	  as	  cell	   types.[140]	   Standardized	   and	   automated	   data	   analysis	   not	   only	   enables	  pattern-­‐finding	   in	   high-­‐dimensional	   data	   but	   has	   the	   further	   advantage	   of	  eliminating	  bias	  and	  increasing	  reproducibility	  in	  gating.[140]	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  6
Results	  The	   main	   question	   addressed	   in	   this	   thesis	   is	   how	   the	   physicochemical	  properties	  of	   lipid	  nanoparticles	  used	  as	  mucosal	  vaccine	  carriers	   influence	  the	  activation	  of	  the	  immune	  response.	  Understanding	  which	  properties	  are	  decisive	  for	   development	   of	   protective	   immunity,	   and	   in	   extension	   the	   identification	   of	  promising	   candidates	   at	   an	   early	   stage,	  might	  help	   rationalizing	   the	  process	  of	  designing	  vaccine	  formulations.	  We	  have	  started	  addressing	  this	  challenge	  using	  antigen-­‐carrying	  lipid	  particles,	  in	  model	  systems	  at	  several	  levels	  of	  complexity.	  Firstly,	   in	   Paper	   I,	   we	   performed	   a	   detailed	   characterization	   of	   the	  immunogenicity	  of	  two	  types	  of	  antigen-­‐carrying	  liposomes	  both	   in	  vitro	  and	  in	  an	  in	  vivo	  mouse	  model.	  Secondly,	  in	  Paper	  II,	  we	  focused	  on	  an	  in	  vitro	  antigen	  presentation	  assay	  to	  both	  investigate	  the	  formulations	  introduced	  in	  Paper	  I	  in	  more	  detail,	  and	  to	  extend	  our	  search	  for	  immunogenic	  antigen	  carriers	  to	  both	  a	  broader,	   with	   respect	   to	   physicochemical	   properties,	   set	   of	   liposome	  formulations	   as	   well	   as	   a	   different	   type	   of	   lipid	   particle:	   the	   lipodisk.	  Additionally,	  presented	  in	  the	  additional	  experimental	  results,	  we	  have	  started	  to	  explore	   single-­‐cell-­‐and-­‐particle	   imaging	   to	   investigate	   the	   interaction	   between	  nanoparticle	   vaccine	   carriers	   and	   the	   outer	   cell	   membrane	   of	   dendritic	   cells,	  representing	  the	  very	  first	  step	  in	  activating	  the	  immune	  response.	  
 	  Paper	  I	  6.1In	  Paper	   I,	  we	  aimed	  at	   combining	   the	  universal	   influenza	  A	  vaccine	   candidate	  CTA1-­‐3M2e-­‐DD	  with	   liposomes	   into	   an	   effective	  mucosal	   vaccine	   formulation.	  CTA1-­‐3M2e-­‐DD	  is	  a	  fusion	  protein	  that	  combines	  the	  mucosal	  adjuvant	  CTA1-­‐DD	  with	   the	   ectodomain	   of	   influenza	   matrix	   protein	   2	   (M2e),	   which	   is	   highly	  conserved	  in	  all	  human	  influenza	  A	  virus	  strains.	  In	  addition	  to	  three	  repeats	  of	  M2e,	   the	   fusion	   protein	   consists	   of	   the	   enzymatically	   active	   cholera	   toxin	   A1	  subunit	   (CTA1),	  which	  has	  an	   immunomodulating	  effect,	   and	  a	  dimer	  of	   the	  D-­‐fragment	   from	  Staphylococcus	  aureus	   protein	  A	   (DD):	   an	   effective	  DC	   targeting	  moiety.	   In	   this	   work,	   the	   fusion	   protein	   was	   formulated	   into	   two	   types	   of	  liposomes:	  PEGylated	  and	  non-­‐PEGylated	  POPC-­‐based	  liposomes	  with	  10%	  Chol.	  	  	  The	  liposomes	  had	  the	  fusion	  protein	  both	  encapsulated	  and	  covalently	  attached	  using	  the	  thiol-­‐maleimide	  reaction	  either	  directly	  to	  the	  lipid	  headgroups	  (non-­‐PEGylated)	  or	  to	  lipid-­‐anchored	  PEG(2000)	  spacers	  (PEGylated).	  The	  liposomes	  were	   characterized	  with	   respect	   to	   size,	   protein	   load	   and	   surface	   charge.	   Both	  formulations	  were	  of	  a	  similar	  size:	  mean	  diameter	  approximately	  150	  nm,	  and	  both	   were	   slightly	   negatively	   charged.	   The	   main	   differences	   between	   the	   two	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formulations,	   in	   terms	   of	   physicochemical	   characteristics,	   besides	   the	  PEGylation,	  were	   that	   the	  non-­‐PEGylated	   formulation	  had	  approximately	   twice	  the	   negative	   charge	   (zeta	   potentials	   of	   -­‐48	   and	   -­‐21	   for	   non-­‐PEGylated	   and	  PEGylated,	   respectively),	   while	   the	   PEGylated	   carried	   approximately	   30-­‐40%	  higher	  protein	  load.	  In	  all	  experiments	  however,	  the	  administered	  fusion	  protein	  dose	  was	  kept	  constant.	  	  The	   immunogenicity	   of	   the	   free	   fusion	   protein	   as	  well	   as	   the	   two	   vectors	  was	  assessed	  using	  two	  in	  vitro	  assays.	  Firstly,	  B	  cells	  (used	  as	  APCs)	  were	  stimulated	  and	   their	   ability	   to	   activate	   M2e-­‐specific	   CD4+	   T	   cells	   were	   assessed	   by	  measuring	   the	   T	   cell	   proliferation.	   It	   was	   found	   that,	   at	   low	   doses,	   particle-­‐associated	  antigen	  more	  effectively	   induces	  T	  cell	  proliferation	  than	  free	  fusion	  protein.	  Secondly,	  an	  assay	  reporting	  the	  primary	  immune	  activation	  assessed	  by	  antigen	  presentation	  by	  DCs	   (further	   used	   in	  Paper	   II)	  was	  used.	   It	  was	   found	  that	  at	  short	  time	  scales,	  up	  to	  1	  hour,	  the	  nonPEGylated	  vector	  more	  effectively	  induced	   antigen	   presentation	   than	   both	   the	   free	   protein	   and	   the	   PEGylated	  vector.	  	  
In	   vivo	   immunogenicity	   assessment	   following	   intranasal	   immunizations	   in	   a	  mouse	  model,	  showed	  that	  the	  non-­‐PEGylated	  vector	  more	  strongly	  induced	  an	  M2e-­‐specific	   CD4+	   T	   cell-­‐response	   than	   both	   the	   free	   fusion	   protein	   and	   the	  PEGylated	   vector.	   Furthermore,	   the	   non-­‐PEGylated	   vector	   gave	   rise	   to	   higher	  levels	   of	   IFN-­‐γ	   and	   serum	   IgG	   than	   the	   PEGylated,	   as	   well	   as	   higher	   local	  secretion	  of	  IgA	  in	  the	  lungs	  than	  the	  free	  protein.	  Additionally,	  we	  observed	  that	  intranasal	   immunization	   using	   the	   non-­‐PEGylated	   vector	   lead	   to	   significant	  protection	  from	  a	  lethal	  challenge	  with	  a	  live	  heterosubtypic	  virus	  (a	  virus	  from	  a	  different	  strain	  than	  the	  M2e	  originated	  from),	  while	  naïve	  mice	  as	  well	  as	  mice	  immunized	   with	   free	   fusion	   protein	   or	   PEGylated	   vectors	   all	   succumbed	   to	  infection.	  	  Taken	  together,	  the	  results	  from	  Paper	  I	  show	  that	  fusion	  protein	  packaged	  into	  non-­‐PEGylated	   liposomes	   more	   efficiently	   induce	   both	   cell-­‐	   and	   antibody-­‐mediated	   immune	   responses	   as	   well	   as	   protection	   against	   a	   lethal	   virus	  challenge,	   than	   both	   PEGylated	   liposomes	   and	   free	   fusion	   protein,	   which	   is	   in	  itself	   already	   an	   effective	   vaccination	   compound.	  As	  previously	  mentioned,	   the	  PEGylated	  and	  non-­‐PEGylated	  vectors	  differed	  with	  respect	  to	  protein	  load	  and	  charge,	   in	  addition	   to	  PEGylation.	  This	   thus	  raises	   the	  question:	  which	  of	   these	  properties	   was	   key	   to	   the	   improved	   immunogenicity	   of	   the	   non-­‐PEGylated	  vector?	  We	   attempted	   to	   address	   this	   question,	   together	   with	   investigation	   of	  additional	  physicochemical	  alterations,	  in	  Paper	  II.	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 Paper	  II	  6.2In	  Paper	  II	  we	  focused	  our	  investigation	  on	  how	  the	  antigen	  presentation	  by	  DCs	  is	  affected	  by	  certain	  physicochemical	  properties	  of	  vaccine	  carriers.	  In	  order	  to	  do	  this,	  and	  simultaneously	  screen	  for	  promising	  carrier	  candidates	  we	  applied	  the	  in	  vitro	  antigen	  presentation	  assay	  introduced	  in	  Paper	  I.	  In	  order	  to	  observe	  the	   kinetics	   of	   the	   antigen	   presentation,	   the	   amount	   of	   functionally	   presented	  antigen	  on	  the	  DC	  surface	  was	  monitored	  at	  various	  time	  points	  up	  to	  24	  h	  after	  administration	   of	   the	   different	   formulations.	   The	   quantification	   of	   the	   antigen	  presentation	   was	   performed	   using	   flow	   cytometry	   and	   immunostaining	   with	  anti-­‐MHC	   II	   and	   the	   YAe	   antibody,	   which	   recognizes	   the	   Ealpha	   (Ea)	   peptide	  when	  presented	   in	   the	  MHC	   II.	  Therefore,	   the	  antigen	  portion	  of	   the	  CTA1-­‐DD-­‐based	   fusion	   protein	   used	   in	   this	   study	   consisted	   of	   the	   Ea	   peptide.	   A	   more	  quantitative	   data	   analysis	   was	   performed	   compared	   to	   in	   Paper	   I,	   including	  quantification	   of	   the	   surface-­‐bound	   MHC	   II	   as	   a	   measure	   of	   the	   level	   of	   DC	  activation.	   Informed	   by	   the	   results	   in	   Paper	   I,	   we	   attempted	   to	   systematically	  vary	  physicochemical	  properties	  of	  fusion	  protein-­‐carrying	  lipid	  particles.	  	  	  Firstly,	   PEGylated	   and	   non-­‐PEGylated	   POPC-­‐based	   liposomes	   (abbreviated	  POPC-­‐PEG	  and	  POPC-­‐PE)	  were	  formulated	  with	  fusion	  protein	  both	  encapsulated	  and	   surface-­‐bound,	   using	   the	   same	   lipid	   composition	   as	   the	   liposomes	  used	   in	  Paper	   I.	   Similarly	   to	   in	   Paper	   I,	   the	   POPC-­‐PEG	   had,	   compared	   to	   its	   non-­‐PEGylated	   counterpart,	   higher	   protein	   load	   and	   zeta	   potential,	   likely	   due	   to	   a	  higher	   content	   of	   negatively	   charged	   lipids	   in	   the	   POPC-­‐PE,	   combined	   with	   a	  charge	  shielding	  effect	  from	  the	  PEG	  in	  POPC-­‐PEG.	  During	  the	  work	  presented	  in	  Paper	  I,	  it	  was	  observed	  that	  the	  non-­‐PEGylated	  vector	  was	  the	  most	  promising	  candidate	   and	   additionally,	   it	   proved	   difficult	   to	   tightly	   control	   the	   portion	   of	  encapsulated	   fusion	   protein.	   Thus,	   secondly,	   the	   amount	   of	   surface-­‐bound	  protein	   on	   non-­‐PEGylated	   POPC-­‐based	   liposomes	  was	   varied	   in	   an	   attempt	   to	  investigate	   the	   influence	   of	   protein	   load	   independently	   from	   PEGylation,	  percentage	  encapsulated	  protein	  and	  surface	  charge.	  Two	  different	  formulations	  with	   approximately	   three	   times	   difference	   in	   protein	   load	   were	   produced.	  Finally,	   to	  assess	   the	   influence	  of	   shape	  and	  size,	  DSPC-­‐based	   lipodisks,	   i.e.	   flat	  bilayer	  circles	  stabilized	  by	  their	  high	  PEG	  content,[34]	  as	  well	  as	  liposomes	  of	  a	  similar	   composition	   (abbreviated	   DSPC-­‐PEG)	   for	   direct	   comparison	   were	  produced.	  The	  lipodisks	  were	  22	  nm	  in	  diameter	  (determined	  using	  Cryo-­‐TEM)	  while	   the	   DSPC-­‐PEG	   were	   on	   average	   127	   nm	   in	   hydrodynamic	   diameter	  (determined	   using	   NTA).	   The	   DSPC-­‐based	   formulations	   differ	   from	   the	   POPC-­‐based	   ones	   in	   a	   significant	   aspect;	   DSPC	   is	   a	   gel	   phase	   lipid	   at	   physiological	  temperature,	   giving	   rise	   to	   particles	   with	   low	   fluidity	   and	   high	   rigidity.	   The	  POPC-­‐based	   liposomes,	   on	   the	   other	   hand,	   are	   in	   the	   liquid	   disordered	   phase,	  which	   means	   that	   the	   membrane	   is	   fluid	   and	   the	   particles	   are	   easily	  deformable.[141]	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We	   observed	   that	   all	   formulations	   gave	   rise	   to	   similar	   kinetics	   in	   the	   antigen	  presentation	  assay;	  a	  fast	  increase	  in	  antigen	  presentation	  in	  the	  first	  few	  hours,	  which	  leveled	  off	  at	  longer	  incubation	  times.	  There	  were	  overall	  little	  discernable	  differences	   among	   the	   POPC-­‐based	   formulations.	   In	   Paper	   I,	   we	   observed	   an	  increased	  antigen	  presentation	  induced	  by	  non-­‐PEGylated	  liposomes	  in	  the	  first	  hour,	  which	  was	  not	  observed	  with	  free	  fusion	  protein	  or	  PEGylated	  liposomes.	  In	   Paper	   II,	   we	   did	   not	   attempt	   to	   resolve	   such	   early	   differences	   but	   instead	  focused	  on	  the	  average	  antigen	  presentation	  over	  the	  whole	  time	  frame,	  in	  order	  to	  give	  a	  quantitative	  estimate	  of	  the	  immunogenicity	  of	  the	  formulations.	  Thus,	  it	  was	  observed	  that	  of	  all	  the	  formulations	  tested,	  only	  the	  DSPC-­‐PEG	  liposomes	  lead	   to	   an	   overall	   increase	   compared	   to	   free	   fusion	   protein.	   This	   increase	  was	  substantial,	   reaching	   approximately	   3	   times	   more	   antigen	   presentation	  compared	  to	  free	  protein,	  as	  well	  as	  an	  increase	  in	  the	  total	  amount	  of	  surface-­‐bound	  MHC	  II.	  This	  increase	  in	  MHC	  II	  indicates	  that	  the	  liposomes	  in	  the	  DSPC-­‐PEG	  formulation	  have	  an	  independent	  adjuvant	  effect	  in	  themselves.	  The	  DSPC-­‐PEG	   had	   comparable	   properties	   when	   it	   came	   to	   size,	   surface	   charge,	   protein	  load	  and	  level	  of	  PEGylation	  as	  POPC-­‐PEG.	  The	  POPC-­‐PEG	  formulation,	  however,	  actually	  lead	  to	  a	  slightly	  reduced	  antigen	  presentation	  compared	  to	  free	  fusion	  protein.	   Why	   does	   the	   DSPC-­‐PEG	   carrier	   increase	   the	   immunogenicity	   of	   the	  vaccine	   formulation	   when	   POPC-­‐PEG	   does	   not?	   Our	   hypothesis	   is	   that	   the	  answer	   lies	   in	   the	   phase	   of	   the	   lipid	   membrane;	   that	   the	   DSPC-­‐PEG	   has	   a	  membrane	  in	  gel	  phase	  while	  the	  POPC-­‐PEG	  membrane	  is	  in	  fluid	  phase	  at	  37°	  C.	  We	  have	  formulated	  two	  hypotheses	  regarding	  the	  underlying	  mechanism.	  	  Firstly,	  we	  hypothesize	  that	  this	  decrease	  in	  immunogenicity	  may	  be	  associated	  with	   an	   increased	   solubilization	   of	   lipid-­‐fusion	   protein	   complexes	   from	   fluid	  phase	   membranes	   as	   compared	   to	   gel	   phase	   membranes,	   together	   with	   a	  reduced	   immunogenicity	   of	   the	   detached	   complexes.	   The	   partioning	   of	   a	   lipid	  into	   the	   aqueous	   phase	   is	   expected	   to	   increase	   if	   the	   hydrophilicity	   of	   the	  headgroup	  is	  increased,	  for	  example	  by	  a	  coupled	  fusion	  protein.	  Additionally,	  it	  is	  expected	  that	  lipid-­‐fusion	  protein	  complexes	  would	  be	  more	  easily	  solubilized	  from	  a	  fluid	  phase	  bilayer	  than	  a	  gel	  phase	  one,	  due	  to	  the	  higher	  fluidity	  and	  less	  compact	   packing	   of	   the	   lipids	   compared	   to	   in	   gel	   phase	   membranes.	   The	  enzymatic	   activity	   of	   CTA1	   is	   required	   for	   the	   adjuvant	   effect	   of	   the	   fusion	  protein.[142]	   Thus,	   the	   decreased	   immunogenicity	   of	   POPC-­‐PEG	   compared	   to	  free	  (non-­‐lipid	  coupled)	  fusion	  protein	  could	  be	  explained	  by	  a	  loss	  of	  enzymatic	  activity	   of	   the	   CTA1	   moiety	   of	   the	   fusion	   proteins	   released	   from	   POPC-­‐PEG	  liposomes.	   CTA1	   has	   a	   hydrophobic	   binding	   site;[143]	   extraction	   of	   the	   lipid-­‐fusion	  protein	  complex	  from	  the	  bilayer	  in	  a	  manner	  where	  the	  lipid	  tails	  might	  reside	   in	   the	   binding	   site	   could	   cause	   the	   formulation	   to	   exhibit	   decreased	  immunogenicity.	   In	   a	   system	   somewhat	   reminiscent	   of	   ours,	   Dubacheva	   et	   al.	  observed	   streptavidin,	   coupled	   via	   a	   single	   lipid	  moiety,	   releasing	   from	   a	   lipid	  membrane.[144]	   They	   hypothesized	   that	   this	   was	   possible	   due	   to	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accommodation	   of	   the	   hydrophobic	   tail	   of	   the	   lipid	   in	   a	   hydrophobic	   binding	  pocket	  on	  streptavidin.[144]	  Thus,	  extraction	  of	  the	  lipid-­‐fusion	  protein	  complex	  from	  the	  bilayer	  in	  a	  manner	  where	  the	  lipid	  tails	  may	  block	  the	  binding	  site	  of	  the	   adjuvanting	   moiety	   of	   the	   fusion	   protein,	   could	   cause	   the	   formulation	   to	  exhibit	   decreased	   immunogenicity.	   It	   also	   follows	   from	   this	   reasoning	   that	   if	   a	  considerable	   portion	   of	   the	   fusion	   protein	   is	   released	   from	   the	   POPC-­‐based	  liposomes,	   the	   decreased	   antigen	   presentation	   induced	   by	   those	   formulations	  compared	  to	  free	  (non-­‐lipid-­‐coupled)	  fusion	  protein	  could	  be	  explained.	  	  Secondly,	  rigidity	  has	  been	  suggested	  as	  an	  important	  factor	  in	  endocytic	  uptake	  of	   nanoparticles;	   theoretical	   modeling	   has	   shown	   that	   high	   bending	   and	  adhesion	  energies	  are	  required	  for	  deformable	  particles	  to	  be	  fully	  enveloped	  by	  the	  cell	  membrane,	  thus	  making	  soft	  particles	  more	  likely	  to	  remain	  trapped	  on	  the	   cell	   surface.[69-­‐71]	   In	   addition,	   it	   has	   been	   confirmed	   experimentally	   that	  rigid	  particles	  are	  taken	  up	  to	  a	  larger	  extent	  than	  soft	  ones.[71,	  72]	  Soft	  POPC-­‐based	   liposomes	  and	  the	  small,	   flat	   lipodisks	  would	  require	   larger	  deformation	  of	   the	   cell	  membrane,	  making	  uptake	  more	   energetically	   costly	   than	   for	   of	   the	  more	   rigid	   DSPC-­‐based	   liposomes.	   Since	   antigen	   uptake	   is	   a	   prerequisite	   for	  antigen	   presentation,	   more	   efficient	   endocytosis	   of	   the	   DSPC-­‐PEG	   formulation	  might	   be	   an	   alternative	   explanation	   to	   why	   it	   performed	   well	   in	   the	   antigen	  presentation	   assay.	   Simultaneously,	   the	   lack	   of	   contrast	   between	   the	   different	  POPC-­‐based	   liposomes	   may	   not	   necessarily	   mean	   that	   the	   physicochemical	  properties	   varied	   among	   them	   generally	   have	   no	   effect,	   but	   merely	   that	   the	  uptake	  is	  equally	  hampered	  by	  all	  the	  POPC-­‐based	  liposomes,	  causing	  them	  to	  be	  trapped	  on	  the	  cell	  surface.	  Before	  concluding	  that	  e.g.	  protein	  load	  has	  no	  effect	  on	   processing	   by	   DCs	   it	   is	   important	   to	   assess	   what	   the	   underlying	   reason	  behind	   the	  observed	  differences,	  or	   lack	   thereof,	   is.	  With	   this	   latter	  hypothesis	  pertaining	  to	  nanoparticle	  rigidity	  and/or	  strength	  of	  antigen	  attachment	  to	  the	  cell	  membrane	  influencing	  cellular	  uptake	  in	  mind,	  we	  are	  now	  in	  the	  process	  of	  developing	  a	  method	  to	  characterize	  and	  quantify	  the	  initial	  interaction	  between	  vaccine	  carrier	  and	  DC.	  	  
 Additional	  experimental	  results:	  TIRF	  microscopy-­‐based	  study	  of	  cell-­‐6.3
particle	  interactions	  The	   first	   step	   in	   activation	  of	   the	   immune	   response	   is	   antigen	  uptake	  by	  APCs	  such	  as	  DCs,	  who	  can	  sample	  their	  environment	  using	  a	  variety	  of	  mechanisms.	  In	   the	   context	   of	   vaccine	   vectors	   it	   remains	   unclear	   how	   the	   physicochemical	  properties	  of	  the	  carrier	  affects	  the	  interactions	  with	  the	  cell	  membrane	  and	  how	  that	   influences	   the	   uptake	   mechanism,	   how	   that	   process	   progresses	   and	   how	  that	  in	  turn	  affects	  the	  downstream	  processing	  of	  the	  antigen.	  We	  aim	  to	  develop	  a	  method	   that	   allows	  us	   to	   visually,	   in	  detail,	   probe	   interactions	  between	   lipid	  vaccine	  particles	  and	  cells	  on	  a	  single-­‐particle	  and	  single-­‐cell	  level.	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Visualizing	  movements	   of	   single	   particles	   requires	   a	   high	   signal-­‐to-­‐noise	   ratio	  and	  high	  spatial	  resolution.	  Therefore,	  TIRF	  microscopy	  was	  used.	  It	  is	  a	  surface	  sensitive	  technique,	  allowing	  for	  visualization	  of	  the	  movements	  of	  particles	  on	  the	   basal	   membrane	   alone	   and	   effectively	   minimizing	   the	   influence	   of	  background	   fluorescence.	   This	   allows	   for	   the	   use	   of	   SPT	   to	   analyze	   particle	  trajectories.	  The	  particles	  were	  tracked	  using	  a	  dedicated	  MATLAB	  script	  created	  within	   the	   division	   of	   Biological	   Physics,	   Chalmers	   University	   of	   Technology	  (available	   upon	   request).	   Additionally,	   we	   used	   a	   topographically	   patterned	  substrate	   with	   micropillars	   (Figure	   11)	   to	   facilitate	   access	   to	   the	   basal	  membrane	   and	   uninhibited	   movement	   compared	   to	   flat	   glass.	   As	   a	   proof	   of	  concept	   a	   fetal	   skin	   dendritic	   cell	   line	   (FSDC),	   derived	   from	  mouse	   [145]	  was	  used,	   as	   robustness	   and	   ease	   of	   handling	   was	   a	   priority	   during	   the	   initial	  development.	  	  	  
	  
Figure	   11.	   FSDCs	   are	   cultured	   on	   a	  micropatterned	   glass	   substrate	  with	   pillars,	   400	   nm	  high	   and	  
with	  1	  µm	  diameter	  and	  spacing.	  This	  provides	   freedom	  of	  movement	  to	   lipid	  particles	  to	   interact	  
with	   the	   basal	   cell	   membrane.	   The	   movements	   of	   the	   particles	   are	   observed	   using	   the	   surface	  
sensitive	   technique	  TIRF	  microscopy,	  which	  selectively	   illuminates	   the	  volume	  closest	   to	   the	  glass	  
substrate.	  SPT	  is	  used	  to	  analyze	  the	  particle	  trajectories.	  Initially,	   two	  different	  micropatterns	  were	   tried:	   the	   pillars	  were	   400	  nm	  high	  and	   their	   diameter	   and	   spacing	   were	   kept	   the	   same	   at	   either	   1	   µm	   or	   2	   µm.	  FSDCs	  were	  cultured	  on	  flat	  glass	  and	  the	  two	  kinds	  of	  topographically	  patterned	  substrates.	   The	   cells	   were	   fixed,	   permeabilized	   and	   stained	   with	   DAPI	   and	  rhodamine	  phallodin	  (nucleus	  and	  F-­‐actin,	  a	  cytoskeleton	  marker,	  respectively).	  The	   morphology	   of	   the	   cells	   was	   inspected	   using	   epifluorescence	   microscopy.	  Since	   these	   cells	   are	   normally	   cultured	   on	   flat	   substrates	   the	   flat	   glass	   sample	  was	  considered	  the	  positive	  control	  (Figure	  12A).	  Here,	  cells	  are	  seen	  to	  stretch	  out,	   forming	   thin	   filaments	   to	   outstretched	   attachment	   points.	   A	   similar	  morphology	  is	  seen	  on	  the	  1µm	  pattern	  (Figure	  12B),	  while	  on	  the	  2	  µm	  pattern	  cells	  appear	  more	  rounded	  and	  with	   fewer	  outreaching	   filaments	  (Figure	  12C).	  Since	   the	   cells	   exhibited	   normal	   morphology	   on	   the	   1	   µm	   pattern,	   this	   was	  chosen	  for	  use	  in	  the	  assay.	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Figure	  12.	  FSDCs	  stained	  with	  DAPI	  (nucleus,	  blue)	  and	  rhodamin	  phalloidin	  (F-­‐actin,	  red),	  cultured	  
on:	  A:	  flat	  glass,	  B:	  glass	  with	  400	  nm	  high	  pillars	  with	  1	  µm	  diameter	  and	  spacing,	  C:	  glass	  with	  400	  
nm	  high	  pillars	  with	  2	  µm	  diameter	  and	  spacing.	  In	   order	   to	   study	   the	   interaction	  between	   lipid	   particles	   and	   cells,	   rhodamine-­‐labelled,	   CTA1-­‐3M2e-­‐DD-­‐functionalized	   liposomes	   (Figure	   13A)	  were	   added	   to	  FSDCs.	  The	  cell	  membrane	  was	  labeled	  with	  PKH67	  in	  order	  to	  visualize	  the	  cells	  (Figure	  13B).	  The	  imaging	  was	  performed	  at	  the	  level	  of	  the	  top	  of	  the	  pillars,	  by	  focusing	   on	   the	   thin	   layer	   of	   chromium	   deposited	   there	   in	   the	   manufacturing	  process,	   and	   the	   field	   of	   view	   was	   the	   same	   in	   Figure	   13A	   and	   B.	   Thus,	   the	  movement	  of	  the	  individual	  particles	  tracked	  using	  SPT	  in	  (Figure	  13C)	  is	  taking	  place	  on	  the	  cell	  surface.	  Time-­‐lapses	  were	  recorded	  at	  a	  speed	  of	  5	  frames	  per	  second.	   No	   particles	   showed	   the	   random	   movement	   patterns	   associated	   with	  free	   diffusion.	   Over	   short	   time	   scales,	   particles	   exhibited	   confined	   movement	  (see	   inset	   in	   Figure	   13C).	   Over	   time	   scales	   of	   several	   minutes,	   directed	  movement	   patterns	   could	   be	   observed	   (see	   main	   image	   in	   Figure	   13C).	   It	   is	  however	  difficult	  to	  determine	  if	  these	  are	  decoupled	  from	  movement	  of	  the	  cell	  itself.	  Particles	  are	  occasionally	  observed	  to	  flicker	  in	  and	  out	  of	  the	  focal	  volume,	  which	   can	   be	   explained	   by	   the	   fact	   that	   the	   normal	  morphology	   of	   DCs	   is	   not	  smooth:	   they	   generally	   have	   a	  multitude	   of	   protrusions	   (dendrites)	   that	   range	  from	   being	   antennae-­‐like	   to	   being	   more	   skirt-­‐like	   depending	   on	   the	   level	   of	  activation.[146]	   Thus,	   it	   can	   be	   expected	   that	   particles	   exhibit	   considerable	  movement	  also	  in	  the	  z-­‐direction.	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Figure	   13.	   A:	   TIRF	   micrograph	   of	   rhodamine-­‐labelled	   CTA1-­‐3M2e-­‐DD-­‐functionalized	   liposomes	  
attached	   to	   the	  surface	  of	   the	  PKH67-­‐labelled	  FSDC	  cell	   seen	   in	  B.	  C:	  Trajectories	  over	   time	  of	   the	  
liposomes	  in	  A.	  Inset	  shows	  detailed	  track.	  In	   conclusion,	   we	   have	   developed	   a	   tool	   that	   enables	   study	   of	   the	   interaction	  between	  vaccine	  carriers	  and	  the	  cell	  surface,	  which	  is	  the	  first	  step	  in	  the	  uptake	  process.	  From	  the	  particle	  trajectories,	   it	   is	  possible	  to	  calculate	  diffusion	  rates.	  Using	  this	  type	  of	  information,	  we	  could	  characterize	  how	  changes	  to	  the	  particle	  properties	  influence	  the	  observed	  membrane	  interactions	  in	  a	  more	  quantitative	  fashion.	   Furthermore,	   by	   quenching	   the	   fluorescence	   of	   the	   extracellular	  particles,	   using	   for	   example	   Trypan	   Blue,	   the	   number	   of	   internalized	   particles	  could	  be	  quantified.	  This	  would	  additionally	  allow	  for	  use	  of	  this	  method	  to	  study	  the	  influence	  of	  particle	  properties	  on	  rate	  and	  degree	  of	  uptake.	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Outlook	  We	   set	   out	   to	   identify	   physicochemical	   characteristics	   of	   lipid-­‐based	   vaccine	  carrier	   particles	   with	   the	   potential	   to	   improve	   the	   immunogenicity	   of	   fusion	  proteins	   based	   on	   the	   mucosal	   adjuvant	   CTA1-­‐DD.	   It	   was	   observed	   that	   the	  liposome	  formulation	  DSPC-­‐PEG	  dramatically	  increased	  the	  antigen	  presentation	  by	   DCs	   and	   we	   hypothesized	   that	   this	   was	   due	   to	   the	   gel-­‐phase	   state	   of	   the	  membrane	  of	   the	   liposomes.	  These	   results	   gave	   rise	   to	  new	  questions	   such	  as:	  What	  is	  the	  mechanism(s)	  behind	  the	  observed	  improvement	  in	  immunogenicity	  obtained	  with	  DSPC-­‐PEG?	  What	  is	  the	  nature	  of	  the	  immune	  response	  elicited	  by	  the	  DSPC-­‐PEG	   formulation	   in	  a	   larger	  sense,	  and	  what	   is	   the	  mechanism	  of	   the	  immune	  response	  modulation?	  Can	  we	  further	   improve	  the	  performance	  of	   the	  DSPC-­‐PEG	   formulation?	   These	   are	   questions	   that	   we	   intend	   to	   address	   in	   the	  continuation	  of	  this	  project,	  as	  described	  in	  this	  chapter.	  	  
 Further	  immunogenicity	  assessment	  of	  DSPC-­‐based	  liposomes	  7.1In	  Paper	  II	   it	  was	  observed,	  in	  an	  antigen	  presentation	  assay	  using	  DCs	  in	  vitro,	  that	  DSPC-­‐based	  liposomes	  used	  as	  vaccine	  vectors	  improve	  the	  immunogenicity	  compared	  to	  POPC-­‐based	  vectors,	  lipodisks	  and	  fusion	  protein	  alone.	  An	  increase	  in	   surface-­‐bound	  MHC	   II	  was	  observed,	  but	   to	   further	  assess	   the	   immunogenic	  potential	  of	   the	  DSPC-­‐PEG	   formulation	   it	   should	  be	  determined	   if	   this	   increase	  was	  due	  to	  upregulation	  of	  MHC	  II	  expression	  or	  merely	  reduced	  recycling	  from	  the	   surface.	   Additionally,	   it	   is	   important	   to	   further	   deepen	   the	   biological	  understanding	   of	   the	   effect	   of	   the	   DSPC-­‐PEG	   on	   the	   DCs,	   in	   terms	   of	   cytokine	  secretion	   and	   expression	   of	   costimulatory	   molecules	   in	   addition	   to	   increased	  surface-­‐bound	   MHC	   II.	   These	   three	   factors	   act	   in	   concert	   to	   impact	   the	  magnitude	   and	   quality	   of	   the	   T	   cell	   response,	   which	   is	   also	   an	   important	  biological	  response	  to	  characterize.	  To	  some	  extent	  this	  can	  be	  done	  in	  vitro,	  and	  by	   focusing	   on	   certain	   well-­‐defined	   parts	   of	   the	   biology	   such	   assays	   are	   very	  useful	   tools	   for	  mechanistic	   studies	   and,	   as	   shown	   in	   Paper	   II,	   for	   performing	  wider	   range	   screening	   than	   what	   is	   practically	   feasible	   in	   vivo.	   However,	   as	  described	   in	   Chapter	   2,	   achieving	   protective	   immunity	   through	   mucosal	  vaccination	   involves	   overcoming	   the	   mucosal	   barrier	   and	   engagement	   of	   the	  adaptive	  immune	  response,	  which	  in	  turn	  activates	  a	  vast	  network	  of	  inter-­‐	  and	  intracellular	   signaling.	   This	  whole	   process,	   from	   vaccine	   administration	   to	   the	  modulation	   of	   the	   balance	   between	   cell-­‐	   and	   antibody-­‐mediated	   immunity,	   is	  difficult	  to	  mimic	  in	  vitro.	  In	  vivo	  trials	  are	  thus	  important,	  in	  their	  own	  right,	  as	  well	   as	   to	   validate	   the	   results	   obtained	   from	   the	   in	   vitro	  antigen	   presentation	  assay.	   Thus,	   in	   collaboration	   with	   Nils	   Lycke’s	   group	   at	   the	   University	   of	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Gothenburg,	  we	  plan	   to	  perform	  an	   in	  vivo	   immunogenicity	   study	  of	   the	  DSPC-­‐PEG	  formulation;	  immunizing	  mice	  intranasally	  and	  quantifying	  serum	  IgG,	  local	  IgA,	   as	   well	   as	   the	   cytokines	   IFN-­‐γ	   and	   IL-­‐17	   and	   characterizing	   the	   antigen-­‐specific	  CD4+	  T	  cell	  response.	  
 Further	  physicochemical	  characterization	  of	  lipid-­‐based	  vaccine	  carriers	  7.2Paper	   II	   presents	   an	   attempt	   to	   identify	   which	   physicochemical	   properties	   of	  vaccine	  carriers	  that	  are	  important	  in	  order	  to	  achieve	  successful	  delivery	  to	  and	  activation	  of	  DCs,	  the	  cell	  type	  targeted	  with	  our	  fusion	  protein.	  We	  believe	  that	  the	  improved	  immunogenicity	  of	  the	  DSPC-­‐PEG	  formulation	  observed	  is	  likely	  to	  have	  its	  basis	   in	  the	  higher	  membrane	  rigidity	  of	  that	  formulation	  compared	  to	  the	   POPC-­‐based	   liposomes.	  However,	   the	  mechanism	  behind	   the	   improvement	  remains	   to	   be	   elucidated,	   which	   motivates	   further	   physicochemical	  characterization	   of	   the	   particles	   to	   understand	   how	   and	   why	   the	   DSPC-­‐PEG	  liposomes	  are	  effective	  while	  the	  other	  formulations	  tested	  are	  not.	  	  	  One	  possible	  reason	  is	  that	  the	  fluid	  phase	  particles	  do	  not	  facilitate	  uptake,	  but	  rather	   remain	   trapped	   on	   the	   cell	   surface	   due	   to	   their	   comparatively	   large	  deformability	  requiring	  high	  bending	  and	  adhesion	  energies	  for	   internalization,	  while	   the	   gel	   phase	   DSPC-­‐PEG	   liposomes	   are	   more	   efficiently	   taken	   up.	  Quantifying	   the	  membrane	  rigidity	  of	   small	  vesicles	   is	  however	  not	   trivial,	   and	  the	  presence	   of	   proteins	   and	  PEG	   at	   the	   vesicle	   surface	   further	   complicate	   the	  matter.	   A	   technique	   that	   has	   previously	   been	   used	   for	   size	   determination	   of	  surface-­‐bound	  vesicles	  with	  a	  complex	  composition	   is	  multi-­‐parametric	  surface	  plasmon	  resonance	  (MPSPR).[147]	  The	  technique	  allows	  for	  quantification	  of	  the	  effective	   film	   thickness,	   which	   is	   translatable	   to	   the	   mean	   size	   of	   deformed	  surface-­‐bound	   particles.	   By	   comparing	   the	   surface-­‐bound	   size	   to	   the	   size	   in	  solution	  measured	   by	   NTA,	   the	   relative	   deformability	   of	   surface-­‐bound	   DSPC-­‐PEG	   and	   the	   POPC-­‐based	   liposomes	   should	   be	   possible	   to	   establish	   also	   for	  protein-­‐	  and	  PEG-­‐decorated	   liposomes.	  Thus,	   it	  might	  be	  possible	   to	  determine	  whether	   a	   large	   deformation	   of	   the	   POPC	   liposomes	   upon	   binding	   to	   the	   cell	  membrane,	   and	   subsequent	   high	   bending	   energy	   required	   for	   internalization,	  offers	   a	   plausible	   explanation	   for	   their	   poor	   immunogenic	   effect.	   To	   provide	   a	  more	  realistic	  picture	  of	  how	  the	  particles	  interact	  with	  the	  cell	  surface,	  MPSPR	  could	   be	   combined	   with	   cell	   membrane-­‐derived	  model	   surfaces	   that	   maintain	  the	  integrity	  and	  mobility	  of	  membrane	  proteins.[148]	  Studying	  the	  deformation	  and	  binding	  of	   lipid	  particles	  on	   cell	  membrane	  mimics	   can	  provide	   important	  structural	   information	   about	   the	   cell-­‐particle	   interface	   but	   only	   limited	   insight	  about	   particle	   processing	   by	   DCs.	   In	   order	   to	   obtain	   information	   about	   the	  behavior	   of	   the	   particles	   at	   the	   cell	   surface	   and	   to	   quantify	   whether	   certain	  formulations	  are	  taken	  up	  to	  a	  larger	  extent	  than	  others,	  we	  intend	  to	  apply	  the	  TIRF-­‐based	   assay	   described	   in	   section	   6.3.	   Detailed	   information	   about	   which	  uptake	  mechanism	   is	   involved	   in	   the	  uptake	  as	  well	   as	   the	   intracellular	   fate	  of	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the	   vectors	   can	   be	   investigated	   by	   fluorescently	   labeling	   cell	   constituents	  relevant	   to	   different	   uptake	   pathways	   and	   intracellular	   compartments,	   and	  observing	   colocalization	   with	   labeled	   vectors	   using	   TIRF	   and	   confocal	  microscopy.[149]	  There	  is	  reason	  to	  believe	  that	  the	  endocytic	  trafficking	  will	  be	  specifically	   influenced	  by	  carrier	  rigidity.	  For	  example,	  Hartmann	  et	  al.	   showed	  that	  rigid	  capsules,	  around	  4	  µm	  in	  diameter,	  were	  more	  slowly	  transported	  to	  the	   lysosomes	   than	   soft	   capsules.[150]	   We	   might	   therefore	   hypothesize	   that	  rigid	  particles	  may	  provide	  the	  antigen	  with	  a	  longer	  time	  frame	  in	  which	  it	  can	  bind	   to	   the	   MHC	   II,	   thus	   increasing	   the	   amount	   of	   presented	   antigen.	   The	  endosomal	   trafficking	   process	   for	   more	   or	   less	   rigid	   liposomes	   could	   be	  characterized	   using	   confocal	   microscopy	   to	   elucidate	   whether	   there	   is	   a	  correlation	   between	   endosomal	   processing	   time	   and	   antigen	   presentation.	  Additionally,	   it	   might	   be	   possible	   to	   probe	   the	   antigen-­‐MHC	   II	   binding	   in	   real	  time	   using	   MHC	   II	   and	   Ea	   peptide	   labeled	   with	   a	   Förster	   resonance	   energy	  transfer	  (FRET)	  pair.	  	  	  Another	   factor	   potentially	   contributing	   to	   the	   contrast	   between	   gel	   and	   fluid	  phase	   liposomes	   pertains	   to	   the	   possibility	   of	   increased	   solubilization	   of	   the	  lipid-­‐anchored	   fusion	   proteins	   from	   the	   fluid	   phase	   particles	   compared	   to	   the	  DSPC-­‐PEG	   formulation.	   It	   is	   possible	   that	   the	   hydrophobic	   portion	   of	   the	   lipid	  would	   obstruct	   the	   binding	   site	   of	   the	   CTA1	   moiety	   of	   the	   fusion	   protein.	   In	  Paper	  I,	  it	  is	  shown	  that	  the	  enzymatic	  activity	  of	  the	  fusion	  protein	  is	  necessary	  for	  the	  immunostimulatory	  effect	  of	  the	  vaccine	  vectors.	  Thus,	  a	  decrease	  in	  the	  portion	   of	   enzymatically	   active	   fusion	   proteins	   in	   the	   fluid	   phase	   formulations	  could	  explain	   their	  poor	  performance	   in	   the	  antigen	  presentation	  assay	   (Paper	  II).	   In	   order	   to	   show	   whether	   there	   is	   indeed	   different	   partitioning	   of	   the	  proteins	   into	  aqueous	  medium	   from	   the	   fluid	  and	  gel	  phase	   formulations,	   time	  correlated	   single	   photon	   counting-­‐Förster	   resonance	   energy	   transfer	   (TRSPC-­‐FRET)	   and	   surface	   analytical	   tools,	   such	   as	   MPSPR	   and	   quartz	   crystal	  microbalance	  with	  dissipation	  monitoring	  (QCM-­‐D)	  will	  be	  used.	  	  	  
 Future	  directions	  in	  lipid-­‐based	  vaccine	  vector	  design	  7.3Based	   on	   the	   current	   knowledge	   presented	   in	   this	   thesis,	   regardless	   of	   the	  reason(s)	  why	  DSPC-­‐PEG	  demonstrates	  increased	  immunogenicity	  compared	  to	  the	  other	  formulations,	  future	  attempts	  at	  exploring	  the	  role	  of	  physicochemical	  properties	   will	   be	   done	   using	   the	   DSPC-­‐PEG	   formulation.	   Since	   the	   DSPC-­‐PEG	  gives	  a	  high	  signal	  in	  the	  antigen	  presentation	  assay	  it	  provides	  a	  good	  starting	  point	   for	   resolving	   differences	   that	   other	   physicochemical	   properties,	   besides	  rigidity,	  might	  cause.	  Similarly,	  the	  DSPC-­‐PEG	  formulation	  will	  be	  used	  as	  a	  basis	  for	  further	  attempts	  to	  reach	  improved	  efficacy.	  	  	  In	  Paper	   II,	   attempts	  were	  made	   to	  elucidate	   the	  combined	  effect	  of	   shape	  and	  size	  using	  lipodisks	  and	  liposomes.	  From	  the	  obtained	  results	  it	  is	  possible	  to	  say	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that	   the	   lipodisks	   are	   not	   advantageous	   as	   vaccine	   carriers	   in	   our	   particular	  system.	  It	  is	  however	  not	  possible	  to	  conclusively	  say	  why:	  is	  it	  an	  effect	  of	  their	  shape,	  size,	  some	  other	   factor	  or	  a	  combination?	  For	   this	  reason,	   it	   is	   logical	   to	  attempt	  to	  investigate	  the	  size	  factor	  on	  its	  own	  using	  the	  well-­‐functioning	  DSPC-­‐PEG	  formulation.	  It	  is	  not	  possible	  to	  vary	  the	  shape	  of	  the	  DSPC-­‐PEG	  liposomes	  while	  maintaining	  the	  composition,	  but	  the	  influence	  of	  size	  can	  be	  investigated.	  Since	  the	  size	  distribution	  of	  extruded	  vesicles	  is	  inherently	  broad,	  it	  may	  be	  that	  only	   a	   small	   size	   fraction	   is	   successfully	   taken	   up	   and	   processed,	   and	   that	   a	  considerable	  amount	  of	  material	  is	  without	  effect.	  Thus,	  the	  influence	  of	  vaccine	  carrier	  size	  is	  an	  interesting	  matter.	  Isolating	  this	  property	  for	  investigation	  can	  be	  done	  in	  a	  fairly	  crude	  manner	  by	  varying	  the	  pore	  size	  of	  the	  membrane	  used	  for	   extrusion	   or	   by	   separating	   different	   size	   subsets	   using	   size	   exclusion	  chromatography.	   Both	   of	   these	  methods	  will	   give	   rise	   to	   a	   narrower	   liposome	  size	   distribution,	   but	   a	   distribution	   of	   sizes	   it	   will	   remain.	   Alternatively,	   the	  method	   to	   create	   liposomes	   of	   a	   tightly	   controlled	   size	   using	   DNA	   templates,	  which	  has	  been	  proposed	  by	  Yang	  et	  al.,	  may	  be	  interesting	  to	  pursue	  for	  a	  more	  clear-­‐cut	  investigation	  of	  the	  influence	  of	  size	  on	  carrier	  immunogenicity.[67]	  	  In	   Paper	   II,	   it	   was	   observed	   that	   changes	   to	   the	   carrier	   design	   could	   achieve	  considerable	  improvement	  in	  immune	  response	  to	  the	  vaccine	  formulation.	  It	  is	  however	   most	   likely	   that	   further	   improvements	   can	   be	   obtained	   by	   further	  tweaking	  the	  design.	  Targeting	  of	  vaccine	  formulations	  to	  certain	  cell	  types,	  such	  as	  DCs,	  is	  a	  core	  concept	  in	  many	  attempts	  to	  create	  successful	  mucosal	  vaccine	  formulations	  (see	  section	  4.7),	  including	  ours.	  It	  is	  not	  well	  known	  how	  the	  DD-­‐portion	  of	  the	  fusion	  proteins	  employed	  in	  Papers	  I	  and	  II	  targets	  DCs.	  Therefore	  there	  is	  currently	  an	  ongoing	  project	  in	  our	  close	  collaborator	  Nils	  Lycke’s	  group	  aiming	  at	   replacing	   the	  DD-­‐portion	  with	   a	   ligand	  of	   a	   known	   receptor,	   such	  as	  CD103,	  CD11c	  or	  Dec205,	  with	  the	  hope	  to	  improve	  targeting	  efficiency.	  It	  would	  be	   interesting	   to	   see	   what	   effect	   such	   changes	   might	   have	   on	   particle	   uptake	  efficiency.	  Changes	  to	  the	  fusion	  protein	  aside,	  the	  advantage	  of	  using	  a	  carrier	  is	  that	   other	   components	   can	   be	   incorporated	   in	   addition	   to	   the	   fusion	   protein.	  Lewis	  X	  oligosaccharides	  (sugar	  polymers)	  have	  been	  used	  to	  target	  DCs	  and	  it	  would	   be	   interesting	   to	   incorporate	   a	   lipid-­‐anchored	   variant	   in	   the	   DSPC	  liposomes.[151]	  Similarly,	  TLR-­‐ligands	  have	  been	  used	  to	  target	  DCs	  (see	  section	  4.7)	   and	   it	   has	   been	   shown	   that	   using	   a	   combination	   of	   ligands	   for	   both	   cell	  surface-­‐	  and	  endosomal	  TLRs	  can	  increase	  the	  CTL	  avidity,	  making	  them	  able	  kill	  target	  cells	  more	  rapidly	  and	  earlier	  in	  the	  infection	  process.[152]	  Additionally,	  an	  increased	  protection	  against	  viral	  challenge	  in	  mice	  was	  observed.[152]	  Thus,	  it	   would	   be	   interesting	   to	   use	   ligands,	   not	   only	   for	   cell	   targeting,	   but	   also	   for	  intentional	  modulation	  of	  the	  immune	  response	  in	  the	  future	  development	  of	  the	  vaccine	  carrier	  formulation.	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